{
  "meta": {
    "title": "00361_Late_Night_Pyq_Pyt_Obg-6",
    "url": "https://brainandscalpel.vercel.app/00361-late-night-pyq-pyt-obg-6-87e4205f.html",
    "scrapedAt": "2025-11-29T17:29:28.544Z"
  },
  "questions": [
    {
      "id": 54785,
      "choices": [
        {
          "id": 218605,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trichomoniasis</span></span></p>"
        },
        {
          "id": 218606,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Neisseria</span></span></p>"
        },
        {
          "id": 218607,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chlamydia</span></span></p>"
        },
        {
          "id": 218608,
          "text": "<p><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bacterial vaginosis</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A woman presents with dysuria and yellowish discharge. Gram staining shows gram-negative diplococci. What is the diagnosis? (INICET MAY 2024)</span></span></span></p>",
      "unique_key": "Q9049722",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585398,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. B) Neisseria</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The presence of gram-negative diplococci on a gram stain is a classic finding in infections caused by <strong>Neisseria gonorrhoeae</strong>, which is a sexually transmitted bacterium responsible for gonorrhea. Neisseria gonorrhoeae typically presents with symptoms such as dysuria (painful urination) and a yellowish or purulent discharge, which aligns with the clinical presentation described in the question.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Gram staining is a key diagnostic tool that helps differentiate bacterial species based on the characteristics of their cell walls. Neisseria gonorrhoeae is a gram-negative diplococcus, meaning it appears as paired spherical bacteria that do not retain the crystal violet stain used in gram staining but do take up the counterstain, appearing pink or red under a microscope.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option A. Trichomoniasis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This is a sexually transmitted infection caused by the protozoan <strong>Trichomonas vaginalis</strong>, which is a flagellated organism. While trichomoniasis can cause dysuria and yellowish discharge, it would not present with gram-negative diplococci on a gram stain. If the organism had flagella, Trichomoniasis would be a consideration, but the gram stain findings rule it out.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Chlamydia:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> Chlamydia trachomatis is another sexually transmitted bacterium that can cause symptoms similar to those of gonorrhea. However, it does not appear as gram-negative diplococci on gram stain. Instead, it is typically detected by nucleic acid amplification tests (NAAT).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. Bacterial vaginosis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> This condition is characterized by an imbalance in the vaginal flora and typically diagnosed using Amsel&#39;s criteria or by identifying clue cells on microscopy. It is not associated with gram-negative diplococci.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The identification of gram-negative diplococci in a patient with dysuria and yellowish discharge is highly indicative of Neisseria gonorrhoeae infection, a common cause of gonorrhea</span></span></span></p>",
      "correct_choice_id": 218606,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55327,
      "choices": [
        {
          "id": 220769,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Leforte colpocleisis</span></span></span></p>"
        },
        {
          "id": 220770,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fothergill surgery</span></span></span></p>"
        },
        {
          "id": 220771,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Shirodkar surgery</span></span></span></p>"
        },
        {
          "id": 220772,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Abdominal sling surgery</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A 24-year-old nulligravida presents with uterine prolapse. There is no cystocele or rectocele. What is the treatment of choice? (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q4199136",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585409,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. D) Abdominal sling surgery</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The correct answer is <strong>abdominal sling surgery</strong>. In a young nulligravida (a woman who has never been pregnant), the preferred treatment for uterine prolapse without cystocele or rectocele is usually a type of sling surgery, also known as hysteropexy. This procedure involves suspending the uterus to a supportive structure within the pelvis, preserving the uterus and maintaining the possibility of future pregnancies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Abdominal sling surgery (Hysteropexy)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This procedure is indicated <strong>for young women</strong>, particularly those who have not completed their family or desire future fertility. It involves attaching the uterus to a ligament or other supportive structure in the pelvis to provide the necessary support and correct the prolapse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Leforte colpocleisis</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This is a procedure typically reserved for <strong>very old women</strong> who are no longer sexually active and not fit for major surgery. It involves closing off the vaginal canal, which is not suitable for a young nulligravida.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Fothergill surgery (Manchester operation)</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: This procedure involves cervical amputation and plication of the cardinal ligaments. It is more suitable <strong>for women who have completed their families</strong> because it can affect future fertility and pregnancy outcomes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Shirodkar surgery</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">: Although similar to sling surgeries, Shirodkar is more commonly associated with cervical cerclage to prevent preterm birth rather than correcting uterine prolapse.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">For a young nulligravida with uterine prolapse and no cystocele or rectocele, <strong>abdominal sling surgery</strong> (hysteropexy) is the treatment of choice to preserve fertility and provide effective prolapse correction.</span></span></span></p>",
      "correct_choice_id": 220772,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5976,
      "choices": [
        {
          "id": 23874,
          "text": "<p><span style=\"font-size:12pt;\">Endometriosis</span></p>"
        },
        {
          "id": 23875,
          "text": "<p><span style=\"font-size:12pt;\">Tubo-ovarian abscess</span></p>"
        },
        {
          "id": 23876,
          "text": "<p><span style=\"font-size:12pt;\">Dermoid cyst</span></p>"
        },
        {
          "id": 23877,
          "text": "<p><span style=\"font-size:12pt;\">Theca lutein cyst</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A teenage patient presented with a history of dysmenorrhea and chronic pelvic pain. On ultrasonography, a transverse vaginal septum was seen. Which of the following is she likely to have?&nbsp;</span>(NEET PG 2021)</p>",
      "unique_key": "Q2768710",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585444,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Endometriosis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Endometriosis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">A transverse vaginal septum is a type of Mullerian anomaly, which can be low, mid, or high and can be complete or incomplete.</span></li><li><span style=\"font-size:12pt;\">It can present as primary amenorrhea with cyclical abdominal pain if complete.</span></li><li><span style=\"font-size:12pt;\">The obstruction to blood flow caused by a transverse vaginal septum can lead to the accumulation of blood in the vagina (hematocolpos) and uterus (hematometra), which can subsequently cause retrograde menstruation and result in endometriosis.</span></li><li><span style=\"font-size:12pt;\">The chronic pelvic pain and dysmenorrhea in this patient are consistent with endometriosis.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Tubo-ovarian abscess:&nbsp;</strong>Tubo-ovarian abscess is typically associated with pelvic inflammatory disease and presents with fever, lower abdominal pain, and a tender adnexal mass. It is not directly related to Mullerian anomalies like a transverse vaginal septum.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Dermoid cyst:&nbsp;</strong>Dermoid cysts (mature cystic teratomas) are benign ovarian tumors that typically do not cause dysmenorrhea or chronic pelvic pain related to menstrual obstruction. They are not associated with Mullerian anomalies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Theca lutein cyst:&nbsp;</strong>Theca lutein cysts are often associated with high levels of human chorionic gonadotropin (hCG) and are seen in conditions like molar pregnancy and multiple gestations. They do not cause symptoms related to menstrual obstruction and are not associated with Mullerian anomalies.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Transverse vaginal septum, a Mullerian anomaly, can cause obstruction to menstrual flow leading to hematocolpos, hematometra, and endometriosis, presenting with dysmenorrhea and chronic pelvic pain.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 34, DC Dutta’s Textbook of Gynecology 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23874,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5974,
      "choices": [
        {
          "id": 23866,
          "text": "<p><span style=\"font-size:12pt;\">Candidiasis</span></p>"
        },
        {
          "id": 23867,
          "text": "<p><span style=\"font-size:12pt;\">Bacterial vaginosis</span></p>"
        },
        {
          "id": 23868,
          "text": "<p><span style=\"font-size:12pt;\">Trichomoniasis</span></p>"
        },
        {
          "id": 23869,
          "text": "<p><span style=\"font-size:12pt;\">Physiological</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 28-year-old married woman who is anxious to conceive presents with copious vaginal discharge, without any itching. Her last menstrual period was 13 days ago. What is the cause of her vaginal discharge?&nbsp;</span>(NEET PG 2021)</p>",
      "unique_key": "Q4524479",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585442,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Physiological</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Physiological:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The discharge described is white with no pruritus and occurs mid-cycle (ovulatory) with a short duration, which is most likely physiological.</span></li><li><span style=\"font-size:12pt;\">Increased physiological discharge is common during:</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">Puberty</span></li><li><span style=\"font-size:12pt;\">Ovulation</span></li><li><span style=\"font-size:12pt;\">Pregnancy</span></li><li><span style=\"font-size:12pt;\">Occasionally during the premenstrual phase</span></li></ul></li><li><span style=\"font-size:12pt;\">It may be cervical or vaginal in origin. A speculum examination of the vagina can distinguish between the two. If the discharge is cervical in origin, an excessive mucoid discharge will be visible at the external os.</span></li><li><span style=\"font-size:12pt;\">Normal discharge appears clear or white, without any odor or itching, and has a pH of 3.8-4.2.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Candidiasis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Typically presents with white, curdy discharge associated with intense itching and vulvar irritation.</span></li><li><span style=\"font-size:12pt;\">The discharge often has a cottage cheese-like appearance.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Bacterial vaginosis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Characterized by a thin, grayish-white, homogenous discharge with a fishy odor, especially noticeable after intercourse.</span></li><li><span style=\"font-size:12pt;\">Itching is less common.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Trichomoniasis:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Presents with frothy, yellow-green discharge with a strong odor.</span></li><li><span style=\"font-size:12pt;\">Associated with vaginal itching, burning, and discomfort during intercourse.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Physiological vaginal discharge is typically clear or white, without odor or itching, and can occur at ovulation, puberty, pregnancy, or occasionally during the premenstrual phase.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/7_SZ5qvMl.jpg\" alt=\"\" width=\"1000\" height=\"489\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 554, DC Dutta’s Textbook of gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23869,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5805,
      "choices": [
        {
          "id": 23191,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystoscopy</span></span></span></p>"
        },
        {
          "id": 23192,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">3 swab test</span></span></span></p>"
        },
        {
          "id": 23193,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRI</span></span></span></p>"
        },
        {
          "id": 91654,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystometry</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the most useful test in vesicovaginal fistula?&nbsp;</span></span>(INICET MAY 2018)</p>",
      "unique_key": "Q5596340",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585417,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Cystoscopy</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystoscopy is the most useful test for diagnosing vesicovaginal fistula (VVF). It allows direct visualization of the bladder and can help identify the exact location, size, and number of fistulas. Additionally, cystoscopy can be used to assess the bladder for any associated injuries or other abnormalities.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 3 swab test:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test is used to identify the type of genitourinary fistula (vesicovaginal or ureterovaginal) but is not as specific as cystoscopy for visualizing the fistula directly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. MRI:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While MRI can provide detailed images of the pelvic structures and help in the diagnosis of fistulas, it is not the first-line investigation. It is more useful in complex cases or when additional information is needed.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Cystometry:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This test evaluates bladder filling and voiding problems and is not specific for diagnosing vesicovaginal fistula.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cystoscopy is the most useful test for directly visualizing vesicovaginal fistulas, determining their size, location, and number, and assessing the bladder for any associated injuries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 417, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23191,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47867,
      "choices": [
        {
          "id": 191063,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">50</span></span></span></span></p>"
        },
        {
          "id": 191064,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">100</span></span></span></span></p>"
        },
        {
          "id": 191065,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">150</span></span></span></span></p>"
        },
        {
          "id": 191066,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">300</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A chorionic villous sampling is done at 12 weeks in a woman whose blood group is B negative. Her husband&#39;s blood group is A positive. What is the dose of Anti D given?&nbsp;(FMGE JANUARY 2024)</span></span></span></span></p>",
      "unique_key": "Q8306486",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585453,
      "difficulty_level": "difficult",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 50</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the case of Rh incompatibility, where the mother is Rh-negative (B negative) and the father is Rh-positive (A positive), there is a risk of fetal-maternal hemorrhage (FMH) during invasive procedures like chorionic villous sampling (CVS). This can lead to the mixing of fetal and maternal blood, potentially causing the mother to form antibodies against the Rh-positive fetal red blood cells. To prevent this alloimmunization, an Anti-D immunoglobulin injection is administered.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The standard practice is to give Anti-D immunoglobulin during any inciting event (e.g., CVS, amniocentesis, abdominal trauma, abruption, placenta previa) and at delivery. Additionally, it is given prophylactically at 28 weeks of gestation to all Rh-negative women.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The dosage of Anti-D depends on the gestational age:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/07/screenshot-2024-06-07-125324.png\" style=\"height:651px; width:400px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Less than 12 weeks: 50 micrograms intramuscularly.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">More than 12 weeks: 300 micrograms intramuscularly.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Since the CVS was performed at 12 weeks, the appropriate dose of Anti-D is 50 micrograms.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For Rh-negative women undergoing an inciting event like chorionic villous sampling at less than 12 weeks gestation, the dose of Anti-D given is 50 micrograms.</span></span></span></span></p>",
      "correct_choice_id": 191063,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23231,
      "choices": [
        {
          "id": 92888,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pain begins after few hours of onset of periods and can last up to 48 hours </span></span></span></p>"
        },
        {
          "id": 92889,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is dependent on psychological factors </span></span></span></p>"
        },
        {
          "id": 92890,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pain begins 3 days prior to the onset of periods and is present up to the second day of the period </span></span></span></p>"
        },
        {
          "id": 92891,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH antagonists are the first line of treatment</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of these statements regarding primary dysmenorrhea is true?&nbsp;</span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q6455908",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585426,
      "difficulty_level": "difficult",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) It Is dependent on psychological factors </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary dysmenorrhea can be dependent on psychological factors.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Secondary dysmenorrhea</span><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is associated with the presence of pelvic pathologies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pain begins after few hours of onset of periods and can last up to 48 hours</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> and </span><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Pain begins 3 days prior to the onset of periods and is present up to the second day of the period</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Pain begins before or with onset of menstrual periods. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. GnRH antagonists are the first line of treatment</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: NSAIDs are the first line of treatment.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary dysmenorrhea, characterized by menstrual pain without underlying pelvic pathology, can be influenced by psychological factors. This type of dysmenorrhea begins before or with the onset of menstrual periods and is typically treated first with NSAIDs, not GnRH antagonists.</span></span></span></p>",
      "correct_choice_id": 92889,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5700,
      "choices": [
        {
          "id": 22772,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pomeroy technique</span></span></span></span></p>"
        },
        {
          "id": 22773,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uchida&#39;s procedure</span></span></span></span></p>"
        },
        {
          "id": 22774,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kroner&#39;s procedure</span></span></span></span></p>"
        },
        {
          "id": 22775,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Irving&#39;s procedure</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fimbriectomy is also known as?</span></span> <span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></p>",
      "unique_key": "Q8117659",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585431,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Kroner&rsquo;s procedure </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fimbriectomy is a method of tubal ligation where the fimbriated end of the Fallopian tube is ligated and excised. This technique is also known as Kroner&rsquo;s procedure.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Pomeroy technique</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In this method, the mid-isthmic portion of the Fallopian tube is elevated and then folded at the midpoint. One or two rapidly absorbable sutures are tied around the double thickness of the tube, and the folded portion is excised sharply.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Uchida&#39;s procedure</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This involves ligating and excising the midportion of the Fallopian tube. The utero-tubal serosa is then hydro-dissected, and the proximal tubal stump is pulled into the mesosalpinx. The peritoneum is closed over the proximal cut end of the tube.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Irving&#39;s procedure</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: In this method, the midportion of the Fallopian tube is ligated and excised. The proximal tubal stump is inserted into an incision made into the myometrium and securely sutured to bury the proximal stump in the myometrium.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fimbriectomy, also known as Kroner&#39;s procedure, involves ligation and excision of the fimbriated end of the Fallopian tube.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 497, DC Dutta&rsquo;s Textbook of Gynecology, 6<sup>th</sup> edition</span></span></strong></span></span></p>",
      "correct_choice_id": 22774,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5806,
      "choices": [
        {
          "id": 23194,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        },
        {
          "id": 23195,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trachelectomy</span></span></span></p>"
        },
        {
          "id": 23196,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conization</span></span></span></p>"
        },
        {
          "id": 23197,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Colposcopy with LEEP</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 40-year-old woman has cervical intraepithelial neoplasia III. What would be the management?&nbsp;</span></span>(INICET MAY 2018)</p>",
      "unique_key": "Q1523374",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585418,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Colposcopy with LEEP</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cervical intraepithelial neoplasia III (CIN 3) is a severe form of cervical dysplasia that is diagnosed by cervical biopsy. The standard treatment for CIN 2 or CIN 3 is an excisional procedure, which aims to remove the affected tissue to prevent progression to invasive cancer.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LEEP (Loop Electrosurgical Excision Procedure):</span></strong></span></span></li>\r\n\t<li style=\"list-style-type:none\">\r\n\t<ul>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LEEP is the excisional procedure of choice for treating CIN 3.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It involves using a thin wire loop that is heated by electric current to excise the transformation zone of the cervix where abnormal cells are located.</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LEEP is also known as LLETZ (Large Loop Excision of the Transformation Zone).</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Hysterectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is a more radical procedure that involves the removal of the uterus. It is generally not the first-line treatment for CIN 3 unless there are other indications, such as concurrent invasive cancer or other gynecological conditions.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Trachelectomy:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This procedure involves removing the cervix while preserving the uterus. It is more commonly used for early-stage cervical cancer in women who wish to preserve fertility.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Conization:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While conization (removal of a cone-shaped piece of tissue from the cervix) is a valid treatment for CIN 3, LEEP is often preferred due to its effectiveness and lower morbidity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">CIN 3 is best treated with an excisional procedure, with the Loop Electrosurgical Excision Procedure (LEEP) being the procedure of choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 328, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23197,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5993,
      "choices": [
        {
          "id": 23942,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">1-A, 2-B, 3-D, 4-C</span></span></span></p>"
        },
        {
          "id": 23943,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿1-B, 2-C, 3-D, 4-A</span></span></span></p>"
        },
        {
          "id": 23944,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿1-A, 2-B, 3-C, 4-D</span></span></span></p>"
        },
        {
          "id": 23945,
          "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿1-D, 2-A, 3-C, 4-B</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Match the following syndromes with their respective karyotypes?&nbsp;</span></span></span>&nbsp;(INICET NOV 2021)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/10/14/screenshot-2024-10-14-185037.jpg\" style=\"height:229px; width:700px\" /></p>",
      "unique_key": "Q9307737",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585450,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 1-A, 2-B, 3-D, 4-C</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRKH syndrome (Mayer-Rokitansky-K&uuml;ster-Hauser):&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This syndrome has a karyotype of <strong>46XX</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer Syndrome:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This condition is characterized by <strong>46XY</strong> karyotype.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner Syndrome:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is due to monosomy X, having a karyotype of <strong>45XO</strong>.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen Insensitivity Syndrome:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This condition occurs in individuals with a karyotype of <strong>46XY</strong>, where there is a complete androgen insensitivity, resulting in a phenotypically female appearance despite having male (XY) chromosomes.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Matching:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">MRKH</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 46XX</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer Syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 46XY</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner Syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 45XO</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen Insensitivity Syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 46XY</span></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Understanding the karyotypes associated with different syndromes helps in diagnosing and managing these conditions effectively. MRKH is associated with 46XX, Swyer syndrome with 46XY, Turner syndrome with 45XO, and Androgen Insensitivity Syndrome with 46XY.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of gynecology 6<sup>th</sup> edition pg 446,447</span></strong></span></span></p>",
      "correct_choice_id": 23942,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55331,
      "choices": [
        {
          "id": 220785,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Temp &gt; 100.4&deg;F occurring 48h after delivery</span></span></span></p>"
        },
        {
          "id": 220786,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Temp &gt; 100.4&deg;F occurring 24h after delivery</span></span></span></p>"
        },
        {
          "id": 220787,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Temp &gt; 100.4&deg;F occurring 12h after delivery</span></span></span></p>"
        },
        {
          "id": 220788,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Temp &gt; 100.4&deg;F occurring 6h after delivery</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Puerperal pyrexia is defined as: (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q4894871",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585413,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans.&nbsp;</span></strong><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">B) Temp &gt; 100.4&deg;F occurring 24h after delivery</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Puerperal pyrexia, also known as postpartum fever, is defined as a maternal temperature exceeding 100.4&deg;F (38&deg;C) after the first 24 hours postpartum. The initial 24-hour period following delivery is not considered because any fever during this time can be a reaction to the stress of labor and delivery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Puerperal pyrexia is defined as a temperature greater than 100.4&deg;F occurring 24 hours after delivery, indicating postpartum infection or other complications.</span></span></span></p>",
      "correct_choice_id": 220786,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6104,
      "choices": [
        {
          "id": 24385,
          "text": "<p><span style=\"font-size:12.0pt;\">1.25 cm below umbilicus</span></p>"
        },
        {
          "id": 24386,
          "text": "<p><span style=\"font-size:12.0pt;\">2.5 cm below umbilicus</span></p>"
        },
        {
          "id": 24387,
          "text": "<p><span style=\"font-size:12.0pt;\">3.5 cm below umbilicus</span></p>"
        },
        {
          "id": 24388,
          "text": "<p><span style=\"font-size:12.0pt;\">5 cm below umbilicus</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Where will be the level of the uterus 48 hours after delivery?</span>(NEET PG 2022)</p>",
      "unique_key": "Q2511950",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585445,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) 2.5 cm below umbilicus</strong></span></p><p>&nbsp;</p><p><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/image_U5u2ZD8.png\" width=\"489\" height=\"498\"></p><ul><li><span style=\"font-size:12pt;\">Following delivery, the uterus is at the level of the umbilicus</span></li><li><span style=\"font-size:12pt;\">it remains at level of umbilicus for 24 hours. Following this, it involutes</span></li><li><span style=\"font-size:12pt;\">It involutes 1.25 cm/ day form the 2nd day onwards</span></li><li><span style=\"font-size:12pt;\">So, after 48 hours (2 days) post-delivery, the uterus will be felt 2.5 cm breadth below the umbilicus</span></li><li><span style=\"font-size:12pt;\">It becomes a pelvic organ (no longer abdominally palpable) by 10-14 days</span></li><li><span style=\"font-size:12pt;\">It becomes the size of a non-pregnant uterus by 6 weeks</span></li><li><span style=\"font-size:12pt;\">alternatively, it reduces by 1 finger breadth / day from 2nd day post partum, till it becomes pelvic organ by 10-14 days</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The uterus will be <strong>2.5 cm below umbilicus </strong>on the second-day post-delivery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 169, DC Dutta’s Textbook of Obstetrics, 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24386,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": "",
      "video_explanation_heading": "",
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5698,
      "choices": [
        {
          "id": 22764,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Testicular feminizing syndrome</span></span></span></span></p>"
        },
        {
          "id": 22765,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gonadal dysgenesis</span></span></span></span></p>"
        },
        {
          "id": 22766,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kallmann syndrome</span></span></span></span></p>"
        },
        {
          "id": 22767,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Turner syndrome</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old girl with primary amenorrhea has the following features. What is the most probable diagnosis?</span></span> <span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal stature</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thelarche - absent</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH, LH - high</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Karyotype - 46 XX</span></span></span></span></li>\r\n</ul>",
      "unique_key": "Q1367573",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585429,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Gonadal dysgenesis </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The probable diagnosis in this case is pure gonadal dysgenesis. Primary amenorrhea with absent secondary sexual characteristics (thelarche) and high levels of FSH and LH indicate hypergonadotropic hypogonadism, which suggests an ovarian cause. The karyotype 46 XX confirms gonadal dysgenesis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Testicular feminizing syndrome/Androgen Insensitivity Syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This condition occurs in individuals with a 46 XY karyotype.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Individuals with this syndrome have absent uterus and ovaries and exhibit secondary sexual development, especially breast development, due to peripheral production of estrogens.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Kallmann Syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is a cause of hypogonadotropic hypogonadism leading to primary amenorrhea.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is associated with anosmia and absent secondary sexual characteristics.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH and LH levels are low in this condition.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Turner Syndrome</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Characterized by a 45 XO karyotype.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Individuals have streak ovaries leading to low estrogen levels and absent secondary sexual characteristics.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH and LH levels are high.</span></span></span></span></li>\r\n\t<li><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A very important feature is short stature, which is not seen in the patient described.</span></span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary amenorrhea with high FSH and LH levels and a 46 XX karyotype indicates gonadal dysgenesis.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 454, DC Dutta&rsquo;s Textbook of Gynecology, 6<sup>th</sup> edition</span></span></strong></span></span></p>",
      "correct_choice_id": 22765,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47869,
      "choices": [
        {
          "id": 191071,
          "text": "<p><span style=\"font-size:12.0pt;\">Surgical excision</span></p>"
        },
        {
          "id": 191072,
          "text": "<p><span style=\"font-size:12.0pt;\">Podophyllin</span></p>"
        },
        {
          "id": 191073,
          "text": "<p><span style=\"font-size:12.0pt;\">5% imiquimod</span></p>"
        },
        {
          "id": 191074,
          "text": "<p><span style=\"font-size:12.0pt;\">Cryotherapy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A pregnant woman presents with a genital lesion as shown below. What is the best treatment option for her?&nbsp;(FMGE JANUARY 2024)</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/06/07/screenshot-2024-06-07-125512.png\" alt=\"\" width=\"300\" height=\"391\"></span></p>",
      "unique_key": "Q5734548",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585454,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. D) Cryotherapy</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The image depicts a genital wart, which is caused by the human papillomavirus (HPV), specifically referred to as condyloma acuminata. In the context of pregnancy, the treatment options for genital warts must be chosen with caution to ensure the safety of both the mother and the fetus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Treatment Considerations in Pregnancy:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Cryotherapy: This method involves freezing the wart with liquid nitrogen, which is a safe and effective treatment for genital warts during pregnancy. It is widely preferred due to its safety profile and effectiveness.</span></li><li><span style=\"font-size:12.0pt;\">Trichloroacetic acid is another safe option during pregnancy for treating genital warts.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Surgical excision:&nbsp;</strong>Though safe, it is not the first-line treatment in most cases unless the warts are extensive.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Podophyllin:&nbsp;</strong>Not recommended during pregnancy due to safety concerns.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. 5% imiquimod:&nbsp;</strong>Also avoided during pregnancy due to safety concerns.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The best treatment option for genital warts in a pregnant woman is cryotherapy, as it is safe and effective during pregnancy.</span></p>",
      "correct_choice_id": 191074,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "FMGE",
        "ImageBased",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5845,
      "choices": [
        {
          "id": 23350,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine artery embolization</span></span></span></p>"
        },
        {
          "id": 23351,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometrial ablation</span></span></span></p>"
        },
        {
          "id": 23352,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal therapy</span></span></span></p>"
        },
        {
          "id": 23353,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hysterectomy</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 33-year-old female patient comes with complaints of menorrhagia for the past 3 months. The duration and regularity of her menstrual cycles are normal. Non- hormonal management has been tried without success. What is the most appropriate next step?</span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (NEET PG 2020)</span></span></span></p>",
      "unique_key": "Q5599674",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585441,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Hormonal therapy </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal therapy is the next best management modality for menorrhagia when non-hormonal management has failed. This includes combined oral contraceptive pills or even progesterone-only devices like the LND-IUS.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">First-line management includes non-hormonal treatment like NSAIDs and Tranexamic acid.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Uterine artery embolization</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Uterine artery embolization is a surgical option and is considered when other treatments fail.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Endometrial ablation</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Endometrial ablation is also a surgical option and should be considered after hormonal therapy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Hysterectomy</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Hysterectomy is the last resort and is used when all other management options fail or are contraindicated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hormonal therapy, including combined oral contraceptive pills or progesterone-only devices like the LND-IUS, is the next best management step for menorrhagia when non-hormonal management has been ineffective.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 197, DC Dutta&rsquo;s Textbook of Gynecology, 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23352,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5764,
      "choices": [
        {
          "id": 23027,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On the action line</span></span></span></p>"
        },
        {
          "id": 23028,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Before the action line</span></span></span></p>"
        },
        {
          "id": 23029,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">On the alert line</span></span></span></p>"
        },
        {
          "id": 23030,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">After the alert line</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a Partogram, where do you start plotting the cervical dilatation?&nbsp;</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(INICET NOV 2017)</span></span></span></span></p>",
      "unique_key": "Q5305038",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585400,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) On the alert line</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the WHO modified partograph, labor progression is charted using alert and action lines. The cervical dilatation is plotted starting in the active phase of labor, typically at 4 cm dilation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alert Line</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Represents a cervical dilation rate of 1 cm per hour. The first marking of cervical dilatation should be on this line.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Action Line</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Plotted 4 hours to the right of the alert line. It indicates when intervention should be considered if labor is not progressing as expected.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. On the action line:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Plotting starts on the alert line, not the action line. The action line is used for intervention planning.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Before the action line:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect as the plotting starts on the alert line.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. After the alert line:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect since plotting should start on the alert line.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a Partogram, cervical dilatation is first plotted on the alert line, which indicates the expected rate of progress in labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></strong><a href=\"https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf\" style=\"color:#0563c1; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://iris.who.int/bitstream/handle/10665/337693/9789240017566-eng.pdf</span></strong></a></span></span></p>",
      "correct_choice_id": 23029,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5918,
      "choices": [
        {
          "id": 23642,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">0.25 mg</span></span></span></p>"
        },
        {
          "id": 23643,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">2 mg</span></span></span></p>"
        },
        {
          "id": 23644,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">20 mg</span></span></span></p>"
        },
        {
          "id": 23645,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">200 mg</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The maximum dose of PGF2 alpha in postpartum hemorrhage is?&nbsp;</span></span>(NEET PG 2019)</p>",
      "unique_key": "Q8729320",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585408,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 2 mg </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prostaglandin F2 alpha (PGF2&alpha;), also known as carboprost, is used for the treatment of postpartum hemorrhage (PPH) due to uterine atony. The therapeutic regimen and maximum dosage are crucial for effective management and patient safety.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dose and Administration:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The approved dose for treating uterine atony with PGF2&alpha; is 0.25 mg administered intramuscularly (IM).</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maximum Dose:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The maximum cumulative dose is 2 mg. This is achieved by administering a total of 8 doses of 0.25 mg each.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dosing Interval:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These doses can be repeated at intervals of 15 to 90 minutes, depending on the clinical response and the patient&#39;s condition.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Contraindications</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Bronchial Asthma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> PGF2&alpha; can cause bronchoconstriction, which makes it contraindicated in patients with bronchial asthma.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Suspected Amniotic Fluid Embolism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Due to its potential to cause pulmonary airway and vascular constriction, it is also contraindicated in cases of suspected amniotic fluid embolism.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. 0.25 mg</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is the single dose administered IM but not the cumulative maximum dose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. 20 mg</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This dose is excessively high and not clinically recommended or safe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. 200 mg</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This dose is not applicable for human use and is far beyond the safe and recommended limits.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The maximum dose of prostaglandin F2 alpha in the management of postpartum hemorrhage is 2 mg, administered in 0.25 mg increments intramuscularly.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 480, DC Dutta&rsquo;s Textbook of Obstetrics, 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23643,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47290,
      "choices": [
        {
          "id": 188771,
          "text": "<p><span style=\"font-size:12.0pt;\">12 weeks</span></p>"
        },
        {
          "id": 188772,
          "text": "<p><span style=\"font-size:12.0pt;\">15 weeks</span></p>"
        },
        {
          "id": 188773,
          "text": "<p><span style=\"font-size:12.0pt;\">6 weeks</span></p>"
        },
        {
          "id": 188774,
          "text": "<p><span style=\"font-size:12.0pt;\">18 weeks</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">When is suction and evacuation done?&nbsp;</span>(FMGE JULY 2023)</p>",
      "unique_key": "Q9672438",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585422,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) 12 weeks</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Suction and evacuation, also known as dilation and evacuation (D&amp;E), is a common surgical method for medical termination of pregnancy. This procedure is typically performed up to 12 weeks of gestation (esp. for 9-12 weeks).</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The process involves:</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12.0pt;\"><strong>Dilation of the cervix</strong>: This can be achieved mechanically using instruments like Hegar's dilators or medically with misoprostol.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Evacuation of uterine contents</strong>: This is done using a suction machine, which can be either a manual vacuum aspirator (MVA) or an electric vacuum aspirator (EVA). In some cases, ovum forceps may also be used to assist in the evacuation.</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Medical methods of termination are usually preferred between 5 to 9 weeks of gestation. After 9 weeks, surgical methods like suction and evacuation become more effective and are the preferred option.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. 15 weeks</strong>: Beyond the recommended period for suction and evacuation; other methods may be considered.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. 6 weeks</strong>: Medical methods are often preferred at this early stage, though suction and evacuation can be performed.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. 18 weeks</strong>: Typically, more advanced surgical methods or induction of labor would be considered for termination at this stage.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Suction and evacuation is best performed up to 12 weeks of gestation, making it the preferred surgical method for early medical termination of pregnancy.</span></p>",
      "correct_choice_id": 188771,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5840,
      "choices": [
        {
          "id": 23330,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Renal agenesis</span></span></span></p>"
        },
        {
          "id": 23331,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal anemia</span></span></span></p>"
        },
        {
          "id": 23332,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Barter syndrome</span></span></span></p>"
        },
        {
          "id": 23333,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anencephaly</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pregnant woman presents for a routine antenatal checkup at 18 weeks of gestation. On abdominal examination, the uterine size was found to correspond to 16 weeks of gestation. On US, oligohydramnios was found. Which of the following is a likely cause?</span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (NEET PG 2020)</span></span></span></p>",
      "unique_key": "Q5520199",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585437,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Renal agenesis </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early onset oligohydramnios can be due to renal anomalies like</span></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B/l renal agenesis</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B/l dysplastic kidneys</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">B/l Autosomal recessive infantile polycystic kidney disease</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options: </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Fetal anemia</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Severe fetal anemia also can cause hydrops and polyhydramnios like in Twin-to-twin transfusion syndrome and Rh iso-immunization</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Barter syndrome&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and<strong> option D. Anencephaly</strong> cause polyhydramnios</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Early onset oligohydramnios can be due to renal anomalies like bilateral renal agenesis, bilateral dysplastic kidneys, or bilateral autosomal recessive infantile polycystic kidney disease.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 352, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23330,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21793,
      "choices": [
        {
          "id": 87136,
          "text": "<p><span style=\"font-size:12pt;\">Previous history of macrosomia</span></p>"
        },
        {
          "id": 87137,
          "text": "<p><span style=\"font-size:12pt;\">Absolute Cephalopelvic disproportion</span></p>"
        },
        {
          "id": 87138,
          "text": "<p><span style=\"font-size:12pt;\">Central placenta previa</span></p>"
        },
        {
          "id": 87139,
          "text": "<p><span style=\"font-size:12pt;\">Advanced CA cervix</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">All the following are indications of caesarean section except?&nbsp;</span>(FMGE JAN 2023)</p>",
      "unique_key": "Q6542591",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585411,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Previous history of macrosomia</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/19/untitled-1040.jpg\" alt=\"\" width=\"1000\" height=\"1104\"></strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Options B, C&nbsp;</strong>and<strong> D</strong> are Absolute Indications for caesarean section. It means vaginal delivery is not possible</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Absolute indications</strong> for caesarean section include:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Central placenta praevia</span></li><li><span style=\"font-size:12pt;\">Contracted pelvis or CPD</span></li><li><span style=\"font-size:12pt;\">Pelvic mass causing obstruction</span></li><li><span style=\"font-size:12pt;\">Advanced CA cervix</span></li><li><span style=\"font-size:12pt;\">Vaginal obstruction (atresia, stenosis)</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Previous history of macrosomia is not an indication for&nbsp;</strong>caesarean section.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Dutta’s textbook of obstetrics page 670</strong></span></p>",
      "correct_choice_id": 87136,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56953,
      "choices": [
        {
          "id": 227201,
          "text": "<p><span style=\"font-size:12.0pt;\">Warfarin</span></p>"
        },
        {
          "id": 227202,
          "text": "<p><span style=\"font-size:12.0pt;\">LMWH (Low Molecular Weight Heparin)</span></p>"
        },
        {
          "id": 227203,
          "text": "<p><span style=\"font-size:12.0pt;\">Fondaparinux</span></p>"
        },
        {
          "id": 227204,
          "text": "<p><span style=\"font-size:12.0pt;\">Apixaban</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 32-year-old woman in her second pregnancy is diagnosed with deep vein thrombosis (DVT) at 30 weeks gestation. What is the drug of choice for her treatment?&nbsp;(NEET PG 2024)</span></p>",
      "unique_key": "Q7786045",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585452,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) LMWH (Low Molecular Weight Heparin)</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Low Molecular Weight Heparin (LMWH)</strong>. LMWH is the preferred treatment for deep vein thrombosis (DVT) during pregnancy due to its safety profile and ease of monitoring. LMWH does not cross the placenta, making it safer for the fetus compared to other anticoagulants. Additionally, LMWH requires less frequent monitoring compared to unfractionated heparin, making it more convenient for both patients and healthcare providers during pregnancy.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Warfarin</strong>: Warfarin is <strong>contraindicated in pregnancy</strong> because it crosses the placenta and can lead to fetal complications, including congenital malformations and bleeding. Warfarin is generally reserved for patients with specific conditions such as mechanical heart valves who were already on the drug before pregnancy, under careful supervision.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Fondaparinux</strong>: While Fondaparinux is an anticoagulant, it is not the first-line choice for DVT in pregnancy. <strong>It is generally considered when LMWH is contraindicated</strong>, such as in cases of heparin-induced thrombocytopenia.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Apixaban</strong>: Apixaban, a direct oral anticoagulant (DOAC), is not recommended in pregnancy due to insufficient safety data. DOACs are <strong>generally avoided during pregnancy</strong> because they can cross the placenta and pose risks to the fetus.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In pregnancy, the drug of choice for treating DVT is Low Molecular Weight Heparin (LMWH) due to its safety and ease of monitoring compared to other anticoagulants</span></p>",
      "correct_choice_id": 227202,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5919,
      "choices": [
        {
          "id": 23646,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial mole</span></span></span></p>"
        },
        {
          "id": 23647,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choriocarcinoma</span></span></span></p>"
        },
        {
          "id": 23648,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental site trophoblastic tumor</span></span></span></p>"
        },
        {
          "id": 23649,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive mole</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational trophoblastic neoplasm does not include?&nbsp;</span></span>(NEET PG 2019)</p>",
      "unique_key": "Q2288941",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585410,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Partial mole </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational trophoblastic disease (GTD) includes a spectrum of conditions characterized by abnormal trophoblastic proliferation. These conditions are broadly classified into molar and non-molar trophoblastic diseases.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Hydatidiform Mole:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Complete Mole</span></strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial Mole</span></strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive Mole</span></strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-Molar Trophoblastic Diseases:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choriocarcinoma</span></strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental Site Trophoblastic Tumor</span></strong></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epithelioid Trophoblastic Tumor</span></strong></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational Trophoblastic Neoplasia (GTN)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">, on the other hand, includes only the malignant forms of trophoblastic disease:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Invasive Mole</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Choriocarcinoma</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental Site Trophoblastic Tumor</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Epithelioid Trophoblastic Tumor</span></strong></span></span></li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A <strong>partial mole</strong> is a type of hydatidiform mole and is considered benign. It is not included under GTN as it does not have malignant potential unless it transforms into an invasive mole, which is rare.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Choriocarcinoma</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a malignant form of GTD and is classified under GTN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Placental Site Trophoblastic Tumor</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is another malignant form of GTD and is included under GTN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Invasive Mole</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: An invasive mole is a malignant transformation of a hydatidiform mole and is included under GTN.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Partial moles are not classified as gestational trophoblastic neoplasia (GTN) because they are generally benign and non-malignant.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 615, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23646,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5975,
      "choices": [
        {
          "id": 23870,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery - Internal iliac artery</span></p>"
        },
        {
          "id": 23871,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery- External iliac artery</span></p>"
        },
        {
          "id": 23872,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - Ovarian artery - Vaginal artery</span></p>"
        },
        {
          "id": 23873,
          "text": "<p><span style=\"font-size:12pt;\">Uterine artery - pudendal artery - Vaginal artery</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A patient developed atonic postpartum hemorrhage after a normal vaginal delivery. She was shifted to the OT and the obstetrician planned ligation of vessels to arrest the bleeding. What is the order of ligation of the blood vessels supplying the uterus?&nbsp;</span>(NEET PG 2021)</p>",
      "unique_key": "Q9738561",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585443,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Uterine artery – Ovarian artery – Internal iliac artery</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Stepwise devascularization in the management of atonic postpartum hemorrhage (PPH) involves:</span><ol><li><span style=\"font-size:12pt;\"><strong>Ligation of the uterine arteries:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">The ascending branch of the uterine artery is ligated at the lateral border between the upper and lower uterine segments.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Ligation of the ovarian and uterine artery anastomoses:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">Done just below the ovarian ligament.</span></li><li><span style=\"font-size:12pt;\">Sometimes, temporary occlusion of the ovarian vessels may be achieved using rubber sleeved clamps.</span></li></ul></li><li><span style=\"font-size:12pt;\"><strong>Ligation of the anterior division of the internal iliac artery:</strong></span><ul style=\"list-style-type:square;\"><li><span style=\"font-size:12pt;\">This step reduces blood flow by decreasing the pulse pressure by 85%.</span></li><li><span style=\"font-size:12pt;\">Ligation can be unilateral or bilateral.</span></li></ul></li></ol></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Uterine artery - Ovarian artery - External iliac artery: </strong>The external iliac artery is not typically involved in the stepwise devascularization for managing atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Uterine artery - Ovarian artery - Vaginal artery: </strong>Ligation of the vaginal artery is not part of the typical sequence in managing atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Uterine artery - pudendal artery - Vaginal artery: </strong>The pudendal artery and vaginal artery are not typically targeted in the stepwise devascularization for atonic PPH.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The stepwise devascularization approach for managing atonic postpartum hemorrhage includes ligation of the uterine arteries, ovarian arteries, and anterior division of the internal iliac arteries in that specific order.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 2023, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23870,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5991,
      "choices": [
        {
          "id": 23934,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Concealed sex</span></span></span></p>"
        },
        {
          "id": 23935,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">True hermaphroditism</span></span></span></p>"
        },
        {
          "id": 23936,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Female pseudohermaphrodite</span></span></span></p>"
        },
        {
          "id": 23937,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male pseudohermaphrodite</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">An 18-year-old girl presented with amenorrhea. On examination, she had normal genitalia &amp; normal breast development. Her tests reveal a 5 alpha-reductase deficiency. What could be the probable diagnosis?&nbsp;</span></span>&nbsp;(INICET NOV 2021)</p>",
      "unique_key": "Q6489656",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585449,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Male pseudohermaphrodite</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The clinical vignette is suggestive of male pseudohermaphroditism.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In pseudohermaphroditism, the sex glands are of one sex while the external genitalia are of the opposite sex.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male pseudohermaphroditism</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> (male intersex) is an association of male gonads with female external genitalia.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In 5 alpha-reductase deficiency, there is a failure of the testis to descend to the scrotum and ill development of the penis, thereby resulting in the female phenotype.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Concealed sex:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Criminals may conceal their sex to avoid detection by changing dress or by other methods. This is not relevant to the clinical scenario presented.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. True hermaphroditism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> In this condition, the glands of both sexes must be present in the same individual. Such cases are very rare. In most cases, the accessory sex gland is atrophic and lacks functional activity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Female pseudohermaphrodite:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The fault is at the level of an enzyme block of 17-hydroxyprogesterone (21 hydroxylase deficiency is the most common cause) leading to defective production of sex steroids. There are features of virilization (clitoromegaly and the fused labioscrotal folds resemble a rudimentary scrotum). The ovaries may descend within the inguinal canal to lie in the labia majora simulating an inguinal testis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Male pseudohermaphroditism involves male gonads with female external genitalia. In 5 alpha-reductase deficiency, there is a failure of the testis to descend and ill development of the penis, resulting in a female phenotype despite having male internal genitalia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of gynecology&nbsp; 6<sup>th</sup> edition pg 443</span></strong><strong>&nbsp;&nbsp;&nbsp;&nbsp; </strong></span></span></p>",
      "correct_choice_id": 23937,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5837,
      "choices": [
        {
          "id": 23318,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amniocentesis</span></span></span></p>"
        },
        {
          "id": 23319,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿MCA doppler</span></span></span></p>"
        },
        {
          "id": 23320,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Cardiotocography</span></span></span></p>"
        },
        {
          "id": 23321,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Amniotic fluid index determination</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Identify the procedure done in the labor room?&nbsp;</span></span>(INICET NOV 2018)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_ttNZkYp.jpg\" style=\"height:189px; width:300px\" /></span></span></span></p>",
      "unique_key": "Q2013437",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585435,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Cardiotocography</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows a procedure called Cardiotocography (CTG). CTG is a method used to monitor the fetal heart rate (FHR) and uterine contractions during pregnancy and labor. It helps assess the well-being of the fetus and identify any signs of fetal distress.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Key points about Cardiotocography (CTG):</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If done antenatally (when the patient is not in labor), it is called a Non-Stress Test (NST).</span></strong></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During labor, CTG is used to continuously monitor the fetal heart rate and contractions to ensure the fetus is not in distress.</span></strong></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Amniocentesis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Amniocentesis is an invasive procedure in which a sample of amniotic fluid is aspirated for prenatal diagnosis or therapeutic purposes. This is not the procedure shown in the image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. MCA Doppler:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> MCA (Middle Cerebral Artery) Doppler is performed to assess fetal growth restriction and fetal anemia. It is an ultrasound procedure and does not match the image shown.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Amniotic Fluid Index (AFI):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> AFI is an ultrasound estimation of amniotic fluid volume. It is not depicted in the image.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Cardiotocography (CTG) is used to monitor the fetal heart rate and uterine contractions during pregnancy and labor. When performed antenatally without labor, it is referred to as a Non-Stress Test (NST).</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 24<sup>th</sup> edition pg339, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg122</span></strong></span></span></p>",
      "correct_choice_id": 23320,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "ImageBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6091,
      "choices": [
        {
          "id": 24333,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succenturiate lobe</span></span></span></p>"
        },
        {
          "id": 24334,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Velamentous insertion of the cord</span></span></span></p>"
        },
        {
          "id": 24335,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Both succenturiate lobe and velamentous insertion</span></span></span></p>"
        },
        {
          "id": 24336,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Normal placenta</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given image depicts:&nbsp;</span></span>(INICET NOV 2022)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/03/inicet-obg-nov-2022-1.jpg\" style=\"height:328px; width:300px\" /></p>",
      "unique_key": "Q2440362",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585434,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Both succenturiate lobe and velamentous insertion</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Succenturiate lobe</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This refers to a placenta with one or more accessory lobes connected to the main part of the placenta by blood vessels. It is characterized by the presence of a smaller, separate lobe in addition to the main placental mass.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Velamentous insertion of the cord</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This occurs when the umbilical cord inserts into the fetal membranes (chorioamnion) rather than directly into the placental mass. The vessels then travel through the membranes to reach the placenta, making them vulnerable to rupture.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows both conditions: a smaller accessory lobe (succenturiate lobe) and the cord inserting into the membranes rather than the placenta (velamentous insertion).</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Succenturiate lobe</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This option is partially correct but does not account for the velamentous insertion.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Velamentous insertion of the cord</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This option is partially correct but does not account for the succenturiate lobe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Normal placenta</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is incorrect as the image shows abnormalities not seen in a normal placenta.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A placenta with both a succenturiate lobe and velamentous insertion of the cord is characterized by the presence of a smaller accessory lobe and the umbilical cord inserting into the fetal membranes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 24<sup>th</sup> edition pg122, 117, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 251,253</span></strong></span></span></p>",
      "correct_choice_id": 24335,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5842,
      "choices": [
        {
          "id": 23338,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Jones metroplasty</span></span></span></p>"
        },
        {
          "id": 23339,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Strassmann metroplasty</span></span></span></p>"
        },
        {
          "id": 23340,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tompkins metroplasty</span></span></span></p>"
        },
        {
          "id": 23341,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transcervical resection of septum</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 24-year-old woman visits the infertility clinic with a complaint of recurrent abortions. Upon investigations, she is found to have a septate uterus. Which of the following corrective procedures has the best obstetric outcome?</span></span><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> (NEET PG 2020)</span></span></span></p>",
      "unique_key": "Q3812074",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585439,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Transcervical resection of septum</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transcervical hysteroscopic resection of the septum has the best obstetric outcome.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The procedure involves the resection of the septum under hysteroscopic guidance. Hence, it doesn&#39;t scar the uterus and avoids the necessity of Cesarean sections for future pregnancies improving the obstetric outcomes. </span></span></span></li>\r\n</ul>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/7.jpg\" style=\"height:216px; width:500px\" /></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Metroplasty is a type of unification procedures in mullerian anomalies</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Jones metroplasty&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">and<strong> Option C. Tompkins metroplasty</strong> are for septate uterus but are not preferred now. As now the treatment of choice is hysteroscopic resection of the septa. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Strassman metroplasty</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Strassman metroplasty is for bicornuate uterus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Transcervical hysteroscopic resection of the septum is the best corrective procedure for a septate uterus to improve obstetric outcomes, as it does not scar the uterus and allows for future vaginal deliveries.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 659, DC Dutta&rsquo;s Textbook of Gynecology, 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23341,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54784,
      "choices": [
        {
          "id": 218601,
          "text": "<p><span style=\"font-size:12.0pt;\">Imperforate hymen</span></p>"
        },
        {
          "id": 218602,
          "text": "<p><span style=\"font-size:12.0pt;\">Transverse vaginal septum</span></p>"
        },
        {
          "id": 218603,
          "text": "<p><span style=\"font-size:12.0pt;\">Vertical vaginal septum</span></p>"
        },
        {
          "id": 218604,
          "text": "<p><span style=\"font-size:12.0pt;\">Mullerian agenesis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A young girl presents with retention of urine and cyclical abdominal pain. On examination, there is a tense bluish bulge seen at the introitus. The diagnosis is? (INICET MAY 2024)</span></p>",
      "unique_key": "Q4701591",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585397,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Imperforate hymen</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">An imperforate hymen is a congenital disorder where the hymen, a thin membrane that typically surrounds or partially covers the vaginal opening, completely obstructs the vaginal opening. This condition can lead to the accumulation of menstrual blood within the vagina (hematocolpos) and uterus (hematometra), resulting in cyclical abdominal pain and urinary retention due to pressure on the bladder.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The classic presentation includes:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Cyclical abdominal pain</strong>: This occurs as menstrual blood accumulates but cannot exit the body, leading to distension and discomfort.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Retention of urine</strong>: The accumulated blood can exert pressure on the bladder and urethra, causing difficulty in urination.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Tense bluish bulge at the introitus</strong>: This is a distinctive finding in imperforate hymen, where the accumulated blood stretches the hymen, causing it to appear bluish and bulging at the vaginal opening.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The treatment for an imperforate hymen typically involves making a cruciate incision in the hymen to drain the accumulated blood (hematocolpos) and relieve the symptoms.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Transverse vaginal septum:</strong> This condition involves a fibrous or muscular wall across the vagina, which can also cause symptoms similar to an imperforate hymen, such as hematocolpos and urinary retention. However, it does not usually present with the characteristic tense bluish bulge at the introitus because the septum is thicker and the blood does not push against the hymen.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Vertical vaginal septum:</strong> A vertical vaginal septum is a partition that divides the vaginal canal into two parts. While it may lead to reproductive issues or dyspareunia, it typically does not cause urinary retention or cyclical pain as described in this case, nor does it present with a bluish bulge.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Mullerian agenesis:</strong> This is a congenital absence of the uterus, cervix, and upper part of the vagina. Patients with this condition often present with primary amenorrhea but do not typically have cyclical abdominal pain or urinary retention. Additionally, there would be no bluish bulge at the introitus because there is no accumulation of blood.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">The presence of cyclical abdominal pain, urinary retention, and a tense bluish bulge at the introitus in a young girl strongly suggests an imperforate hymen. Early diagnosis and surgical intervention can prevent complications and relieve symptoms.</span></p>",
      "correct_choice_id": 218601,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5761,
      "choices": [
        {
          "id": 23015,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low MSAFP, high hCG, low UE3</span></span></span></p>"
        },
        {
          "id": 23016,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High MSAFP, low hCG, high UE3</span></span></span></p>"
        },
        {
          "id": 23017,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Low MSAFP, high hCG, high UE3</span></span></span></p>"
        },
        {
          "id": 23018,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">High MSAFP, low hCG, low UE3</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pregnant woman has a fetus with Down&#39;s syndrome. Triple test done at 15-16 weeks will have?&nbsp;</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(INICET NOV 2017)</span></span></span></span></p>",
      "unique_key": "Q9975201",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585399,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Low MSAFP, high hCG, low UE3</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The triple and quadruple test is done between 15 &ndash; 21 weeks.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Components of Triple test are: Free &beta; hCG, unconjugated Estriol (uE3) and Maternal Serum &alpha;-fetoprotein.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Components of the Quadruple test are: Free &beta; hCG, unconjugated Estriol (uE3), Maternal Serum &alpha;-fetoprotein. And Inhibin A.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/10/03/untitled-296.jpg\" style=\"height:146px; width:900px\" /></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">*Easy to remember: <strong>B</strong> for <strong>B</strong>ig; so in Down&rsquo;s syndrome; <strong>B</strong>eta hCG and Inhi<strong>B</strong>in A: <strong>B</strong>ig/ Increased</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The triple test results for Down&#39;s syndrome typically show low MSAFP, high hCG, and low uE3.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page 859, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23015,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "DiagnosisBased",
        "Factual"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20497,
      "choices": [
        {
          "id": 81950,
          "text": "<p><span style=\"font-size:12pt;\">Advise HPV vaccine</span></p>"
        },
        {
          "id": 81951,
          "text": "<p><span style=\"font-size:12pt;\">Screen for BRCA mutation</span></p>"
        },
        {
          "id": 81952,
          "text": "<p><span style=\"font-size:12pt;\">Screen for PTEN mutation</span></p>"
        },
        {
          "id": 81953,
          "text": "<p><span style=\"font-size:12pt;\">Perform cervical biopsy</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 52-year-old woman came to the OPD with a diagnosis of advanced cervical cancer. She has a 14-year-old daughter. What advice would you give for her daughter? (NEET PG 2023)</span></p>",
      "unique_key": "Q5326909",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585405,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. A) Advise HPV vaccine</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The patient's 14-year-old daughter should be advised to take the HPV vaccine.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Screening CA cervix begins at the age of 25 years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><u>HPV vaccine</u></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Contains recombinant VLP (L1 synthetic capsid protein)</span></li><li><span style=\"font-size:12pt;\">Types –</span><ul><li><span style=\"font-size:12pt;\">Cervarix: Bivalent (16,18)</span></li><li><span style=\"font-size:12pt;\">Gardasil: Quadrivalent (6,11,16,18)</span></li><li><span style=\"font-size:12pt;\">Gardasil 9: Nonavalent (6, 11, 16, 18, 31, 33, 45, 52, 58)</span></li><li><span style=\"font-size:12pt;\">Dosing as per IAP:</span><ul><li><span style=\"font-size:12pt;\">Girls 9 to 14 years: 2 doses</span></li><li><span style=\"font-size:12pt;\">&gt; 15 years: 3 doses</span></li></ul></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">On June 1, 2023 there will be the launch of Indian indigenous vaccine called Cervavac , quadrivalent vaccine produce by Serum Institute of India (6, 11, 16, 18).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">WHO’s Safe Advisory Group (SAGE) in 2021 advised regarding updating dose schedules for HPV as follows:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">One or two-dose schedule for the primary target of girls aged 9-14</span></li><li><span style=\"font-size:12pt;\">One or two-dose schedule for young women aged 15-20</span></li><li><span style=\"font-size:12pt;\">Two doses with a 6-month interval for women older than 21</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Immunocompromised individuals, including those with HIV, should receive three doses if feasible, and if not at least two doses. There is limited evidence regarding the efficacy of a single dose in this group.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Screen for BRCA mutation</strong>: BRCA mutation causes breast cancer, ovarian cancer, endometrial cancer</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Screen for PTEN mutation</strong>: PTEN mutation (chromosome 10) causes Cowden syndrome, has 20-30% risk of developing endometrial cancer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Perform cervical biopsy</strong>: Cervical biopsy is not indicated.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The HPV vaccine is essential for preventing cervical cancer and should be administered to girls aged 9 to 14 years, ideally before the onset of sexual activity.</span></p>",
      "correct_choice_id": 81950,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6021,
      "choices": [
        {
          "id": 24054,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graph A</span></span></span></p>"
        },
        {
          "id": 24055,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph B</span></span></span></p>"
        },
        {
          "id": 24056,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph C</span></span></span></p>"
        },
        {
          "id": 24057,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Graph D</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following graphs represents normal response to OGTT?&nbsp;</span></span>(INICET MAY 2022)</p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/1_QetTw5P.jpg\" style=\"height:197px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q7698609",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585401,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Graph D</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The normal response to an Oral Glucose Tolerance Test (OGTT) is depicted by Graph D. During an OGTT, a patient ingests a specified amount of glucose (commonly 75 grams), and blood glucose levels are measured at intervals to evaluate how well the body handles glucose. In a normal response:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Blood glucose levels rise to a peak within 1 hour after ingestion.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Glucose levels then decline and return to baseline by 2 hours.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The glucose levels do not exceed the renal threshold at any point during the test.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This pattern reflects the body&#39;s effective regulation of blood glucose levels and the normal function of insulin.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Graph A:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Graph A might depict an abnormal glucose tolerance curve, such as one seen in impaired glucose tolerance or gestational diabetes, where glucose levels remain elevated for a prolonged period or fail to return to baseline.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Graph B</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Graph B could show a response with an abnormal peak or delayed return to baseline, indicative of glucose intolerance or a diagnostic criterion for diabetes mellitus.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Graph C</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Graph C might represent an exaggerated glucose peak or prolonged elevated glucose levels, suggesting a pathological glucose tolerance response consistent with diabetes.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A normal OGTT response features a peak in blood glucose levels within 1 hour, followed by a return to baseline levels within 2 hours, without exceeding the renal threshold.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><a href=\"https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM\" style=\"color:#0563c1; text-decoration:underline\"><strong>https://www.researchgate.net/publication/301045468_VARIANTS_OF_ORAL_GLUCOSE_TOLERANCE_TEST_OGTT_CURVE_IN_GESTATIONAL_DIABETES_MELLITUS_GDM</strong></a></span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>",
      "correct_choice_id": 24057,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5939,
      "choices": [
        {
          "id": 23726,
          "text": "<p><span style=\"font-size:12.0pt;\">Copper T</span></p>"
        },
        {
          "id": 23727,
          "text": "<p><span style=\"font-size:12.0pt;\">Implanon</span></p>"
        },
        {
          "id": 23728,
          "text": "<p><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation</span></p>"
        },
        {
          "id": 23729,
          "text": "<p><span style=\"font-size:12.0pt;\">SC DMPA</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which of the following is not a long-acting reversible contraceptive method?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q1244543",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585420,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. C) Laparoscopic tubal ligation</strong></span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Laparoscopic tubal ligation</strong> is a permanent form of contraception and is not classified as a long-acting reversible contraceptive (LARC). It involves the surgical closure or blocking of the fallopian tubes to prevent pregnancy permanently.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Long-acting reversible contraceptive (LARC) methods</strong> are effective for extended periods and can be reversed if desired. They include:</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option A. Copper T:</strong> Correct. Copper T is an intrauterine device (IUD) that can provide contraception for several years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Implanon:</strong> Correct. Implanon is a type of contraceptive implant that provides effective contraception for several years.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. SC DMPA:&nbsp;</strong>This is a LARC. It is a sub cutaneous preparation of depot medroxy progesterone acetate and is administered once in 3 months</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p><br><span style=\"font-size:12.0pt;\">Laparoscopic tubal ligation is a permanent method of contraception and is not a long-acting reversible contraceptive (LARC).</span></p>",
      "correct_choice_id": 23728,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5990,
      "choices": [
        {
          "id": 23930,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Luteal phase LH</span></span></span></p>"
        },
        {
          "id": 23931,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post luteal phase LH</span></span></span></p>"
        },
        {
          "id": 23932,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH in the follicular phase</span></span></span></p>"
        },
        {
          "id": 23933,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Mullerian hormone (AMH)</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is the best measures ovarian reserve?&nbsp;</span></span></span>(INICET NOV 2021)</p>",
      "unique_key": "Q7856557",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585448,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Anti-Mullerian hormone (AMH)</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Mullerian Hormone (AMH)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is a glycoprotein secreted by the granulosa cells of pre-antral follicles. It is the best marker of ovarian reserve because it can be tested on any day of the cycle.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Values and Interpretation:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Normal value:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> 2-6.8 ng/mL</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Poor ovarian reserve:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> &lt;1 ng/mL</span></span></span></li>\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Polycystic Ovary Disease (PCOD) and Hyperstimulation Syndrome:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> &gt;10 ng/mL</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Tests for ovarian reserve:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH levels:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Measured in the early follicular phase (Day 2 or 3 of the menstrual cycle). High FSH means the ovarian reserve is getting depleted.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Serum estradiol values:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Measured on day 3 of the cycle. Serum estradiol &gt;75 pg/mL indicates ovarian hypofunction.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antral follicular count on ultrasound:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Counts less than 4-5 on days 2-5 denote poor response to hormones.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Inhibin B:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Values &lt;40 pg/mL indicate poor reserve.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Luteal phase LH:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Not a reliable measure of ovarian reserve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Post luteal phase LH:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Not a reliable measure of ovarian reserve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. FSH in the follicular phase:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While useful, it is less reliable than AMH for assessing ovarian reserve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anti-Mullerian Hormone (AMH) is the best marker of ovarian reserve as it can be tested on any day of the menstrual cycle and provides a reliable measure of the ovarian reserve.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of gynecology 6<sup>th</sup> edition Pg 528,529, William&rsquo;s textbook of gynecology 3<sup>rd</sup> edition pg435</span></strong></span></span></p>",
      "correct_choice_id": 23933,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5758,
      "choices": [
        {
          "id": 23003,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysgerminoma</span></span></span></p>"
        },
        {
          "id": 23004,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endodermal sinus tumor</span></span></span></p>"
        },
        {
          "id": 23005,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Malignant teratoma</span></span></span></p>"
        },
        {
          "id": 23006,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mucinous cystadenocarcinoma</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 16-year-old female patient presents with an ovarian mass. On further evaluation, her serum biomarkers are found to be normal except for LDH, which is found to be elevated. The most likely diagnosis is:&nbsp;</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(INICET NOV 2017)</span></span></span></span></p>",
      "unique_key": "Q3613268",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585416,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Dysgerminoma</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given clinical history of a 16-year-old female presenting with an ovarian mass with raised LDH points towards the diagnosis of dysgerminoma. Dysgerminomas usually arise in young women or in children, with an average incidence at the age of 20. They currently account for approximately one-third of all malignant ovarian germ cell tumors and are the most common malignant ovarian tumors found in pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Endodermal sinus tumor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is typically associated with elevated alpha-fetoprotein (AFP), not LDH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Malignant teratoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This type of tumor does not typically present with elevated LDH as the sole abnormal marker.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Mucinous cystadenocarcinoma:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This epithelial ovarian tumor is usually associated with elevated CA-125, not LDH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Dysgerminoma is the most likely diagnosis in a young female with an ovarian mass and elevated LDH levels.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 381, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23003,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "DiagnosisBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23232,
      "choices": [
        {
          "id": 92892,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 alpha reductase deficiency </span></span></span></p>"
        },
        {
          "id": 92893,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">17 alpha hydroxylase deficiency </span></span></span></p>"
        },
        {
          "id": 92894,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Androgen insensitivity syndrome </span></span></span></p>"
        },
        {
          "id": 92895,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Swyer syndrome</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A 15-year-old girl comes in with primary amenorrhea and indications of virilization. She displays underdeveloped breasts and pubic hair consistent with prepubertal stages, rated at Tanner stage 2. She has a closed-off vaginal canal and noticeable enlargement of the clitoris. Despite her female sex, her testosterone levels are within the male range. Her genetic makeup is 46XY. What is the likely medical diagnosis in this case?&nbsp;</span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q9146024",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585428,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) 5 alpha reductase deficiency </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given scenario points to a diagnosis of 5 alpha reductase deficiency.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5 alpha reductase deficiency causes inability to convert testosterone to DHT.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When DHT levels are low, newborns will possess external genitalia with a feminine appearance. These youngsters are commonly brought up as girls until they reach puberty, at which point they begin to display signs of masculinization due to the influence of testosterone. As a result, clitoromegaly becomes evident. The absence of estrogen conversion from testosterone results in limited breast growth. Scanty pubic hair is observed since its growth is contingent on both testosterone and dihydrotestosterone.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/08/15/whatsapp-image-2023-06-12-at-190121011010201026_page_49.jpg\" style=\"height:533px; width:700px\" /></span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. 17 alpha hydroxylase deficiency</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Leads to reduced formation of corticosteroids, sex hormones and increased mineralocorticoids (causing hypokalemia and hypertension). Patient with XY chromosome presents with atypical genitalia and undescended testes. Patient with XX chromosome lacks secondary sexual development.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Androgen insensitivity syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Defect in androgen receptor resulting in female-appearing genetic male (46, XY); female external genitalia with scant axillary and pubic hair, rudimentary vagina; uterus and fallopian tubes absent due to persistence of anti-Mullerian hormone from testes. Patients develop normal functioning testes. Patient has increased testosterone, estrogen &amp; LH as compared to other sex chromosome disorders.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Swyer syndrome</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: 46 XY gonadal dysgenesis; Absent secondary sexual characters, but normal female internal and external genitalia. Gonadectomy needs to be done.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">5-alpha reductase deficiency causes primary amenorrhea and virilization in genetic females (46XY), resulting in the inability to convert testosterone to dihydrotestosterone (DHT). This leads to female external genitalia at birth and masculinization at puberty, with signs such as clitoromegaly and underdeveloped breasts.</span></span></span></p>",
      "correct_choice_id": 92892,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6100,
      "choices": [
        {
          "id": 24369,
          "text": "<p><span style=\"font-size:12pt;\">Fetal head 5/5 palpable on abdominal examination</span></p>"
        },
        {
          "id": 24370,
          "text": "<p><span style=\"font-size:12pt;\">Two contractions lasting for 10 seconds in 10 minutes</span></p>"
        },
        {
          "id": 24371,
          "text": "<p><span style=\"font-size:12pt;\">More than 5 cm cervical dilatation with complete effacement</span></p>"
        },
        {
          "id": 24372,
          "text": "<p><span style=\"font-size:12pt;\">Rupture of membranes</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A primigravida presents to the labor room at 40 weeks of gestation with lower abdominal pain. She has been in labor for 3 hours. Which of the following will determine if she is in active labor?</span>(NEET PG 2022)</p>",
      "unique_key": "Q5965505",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585440,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) More than 5 cm cervical dilatation with complete effacement</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\"><strong>More than 5 cm cervical dilatation with complete effacement:</strong></span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12pt;\">According to the World Health Organization (WHO) Labor Care Guide (LCG), active labor begins at more than 5 cm of cervical dilatation.</span></li><li><span style=\"font-size:12pt;\">The older definition of active labor was at 4 cm of cervical dilatation.</span></li><li><span style=\"font-size:12pt;\">The American College of Obstetricians and Gynecologists (ACOG) now defines active labor as beginning at more than 6 cm of cervical dilatation.</span></li><li><span style=\"font-size:12pt;\">Complete effacement indicates that the cervix has thinned out, which is a key indicator of active labor progression.</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Fetal head 5/5 palpable on abdominal examination:&nbsp;</strong>This indicates that the fetal head is still high in the pelvis and not yet engaged. It does not determine active labor.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Two contractions lasting for 10 seconds in 10 minutes:&nbsp;</strong>This frequency and duration of contractions are not sufficient to determine active labor. Active labor typically involves regular, strong contractions lasting 45-60 seconds and occurring every 2-3 minutes.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Rupture of membranes:&nbsp;</strong>While rupture of membranes can occur during labor, it is not a definitive indicator of active labor. Cervical dilation and effacement are more reliable indicators.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Active labor is determined by more than 5 cm of cervical dilatation with complete effacement, according to the WHO Labor Care Guide.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 138, DC Dutta’s Textbook of Obstetrics, 8<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24371,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47871,
      "choices": [
        {
          "id": 191079,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous upper segment cesarean</span></span></span></span></p>"
        },
        {
          "id": 191080,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous lower segment cesarean</span></span></span></span></p>"
        },
        {
          "id": 191081,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous J-shaped cesarean</span></span></span></span></p>"
        },
        {
          "id": 191082,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous T-shaped cesarean</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A G2P1L1 with a previous cesarean section now presents at term. Which of the following is most favorable for a vaginal birth? </span></span><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(FMGE JANUARY 2024)</span></span></span></span></p>",
      "unique_key": "Q8077385",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585456,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Previous lower segment cesarean</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The type of uterine incision from a previous cesarean section significantly impacts the safety and likelihood of a successful vaginal birth after caesarean (VBAC). </span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The lower segment cesarean section (LSCS) involves a transverse incision made in the lower, thinner part of the uterus. This type of incision is most favorable for a vaginal birth due to its lower risk of uterine rupture during labor, which is around 0.2%.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options: </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Incision Types and Associated Risks:</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Previous upper segment cesarean:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This is also known as a classical cesarean section, where the incision is made vertically in the thicker, upper part of the uterus. The risk of uterine rupture with this type of incision is significantly higher, ranging from 4-9%.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Previous J-shaped cesarean:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This incision extends from the lower segment into the upper segment, increasing the risk of rupture to 4-9%.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Previous T-shaped cesarean:&nbsp;</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This incision combines a lower segment transverse incision with a vertical extension into the upper segment, also associated with a 4-9% risk of rupture.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The most favorable incision for a vaginal birth after a previous cesarean section is the lower segment transverse incision due to its lower risk of uterine rupture during labor.</span></span></span></span></p>",
      "correct_choice_id": 191080,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 55324,
      "choices": [
        {
          "id": 220757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron prophylaxis is given for 6 months antepartum and 6 months postpartum</span></span></span></p>"
        },
        {
          "id": 220758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron prophylaxis is started at 14 weeks and continued for 6 weeks after delivery</span></span></span></p>"
        },
        {
          "id": 220759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron prophylaxis starts in the 1st trimester and continues till 6 weeks postpartum</span></span></span></p>"
        },
        {
          "id": 220760,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron prophylaxis is given 6 months antepartum and 3 months postpartum</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">As per Anemia Mukt Bharat, which is the correct statement regarding iron prophylaxis in pregnant women? (FMGE JULY 2024)</span></span></span></p>",
      "unique_key": "Q8751917",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585407,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Iron prophylaxis is given for 6 months antepartum and 6 months postpartum</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The Anemia Mukt Bharat (AMB) initiative outlines that iron prophylaxis for pregnant women should start from the 14th week of pregnancy and continue throughout the pregnancy (approximately 6 months) and for 6 months postpartum. The recommended dosage is one red-colored, sugar-coated tablet containing 60 mg of elemental iron and 0.5 mg of folic acid daily. This regimen helps in preventing iron deficiency anemia and folate deficiency anemia during and after pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Iron prophylaxis for pregnant women under the Anemia Mukt Bharat initiative is given from 14 weeks of pregnancy and continues for 6 months postpartum.</span></span></span></p>",
      "correct_choice_id": 220757,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5949,
      "choices": [
        {
          "id": 23766,
          "text": "<p><span style=\"font-size:12.0pt;\">Oligomenorrhea</span></p>"
        },
        {
          "id": 23767,
          "text": "<p><span style=\"font-size:12.0pt;\">Hypomenorrhea</span></p>"
        },
        {
          "id": 23768,
          "text": "<p><span style=\"font-size:12.0pt;\">Dysmenorrhea</span></p>"
        },
        {
          "id": 23769,
          "text": "<p><span style=\"font-size:12.0pt;\">Menorrhagia</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Asherman syndrome is most commonly associated with?&nbsp;</span>(INICET MAY 2021)</p>",
      "unique_key": "Q8163052",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585425,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Hypomenorrhea</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Asherman syndrome is the presence of uterine synechiae, due to the destruction of the endometrium. It can occur because of</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Trauma to the endometrium following vigorous curettages such as incomplete abortion, postpartum hemorrhage, and elective abortion.</span></li><li><span style=\"font-size:12.0pt;\">Genital tuberculosis</span></li></ul></li><li><span style=\"font-size:12.0pt;\">C/F: Following a D &amp; C, they present with</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">Hypomenorrhea</span></li><li><span style=\"font-size:12.0pt;\">Secondary amenorrhoea</span></li><li><span style=\"font-size:12.0pt;\">Secondary infertility</span></li></ul></li><li><span style=\"font-size:12.0pt;\">The diagnosis is made by</span><ul style=\"list-style-type:circle;\"><li><span style=\"font-size:12.0pt;\">HSG: Moth eaten appearance/ intra cavitary filling defects</span></li><li><span style=\"font-size:12.0pt;\">Hysteroscopy: Intra uterine adhesions are seen</span></li></ul></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-171526.png\" alt=\"\" width=\"500\" height=\"234\"></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Management: Hysteroscopic adhesiolysis f/b insertion of an IUCD for 3 months and giving estrogen to build the endometrium</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>&nbsp;Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Oligomenorrhea</strong>: This refers to infrequent menstruation, which is not the primary symptom of Asherman syndrome. Although it can occur, hypomenorrhea is more characteristic of the condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Dysmenorrhea</strong>: This means painful menstruation, which is not typically associated with Asherman syndrome.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt;\"><strong>Menorrhagia</strong>: This refers to heavy menstrual bleeding. Asherman syndrome usually leads to hypomenorrhea rather than menorrhagia due to the reduced endometrial surface area.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Asherman syndrome is most commonly associated with hypomenorrhea due to intrauterine adhesions following endometrial trauma.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Ref: Page no 459, DC Dutta’s Textbook of gynecology 6<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 23767,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5823,
      "choices": [
        {
          "id": 23262,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supine with wedge under right hip</span></span></span></p>"
        },
        {
          "id": 23263,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Semi fowlers</span></span></span></p>"
        },
        {
          "id": 23264,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Trendelenburg with legs stirrup</span></span></span></p>"
        },
        {
          "id": 23265,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prone position</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman presents with prolonged labor in emergency. She is being taken for a Cesarean section. Which of the following is the correct position in which the nurse should keep the patient on the OT table?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q6047962",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585432,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Supine with wedge under right hip</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The preferred position for a cesarean section is supine with a wedge under the right hip. This positioning is crucial to prevent supine hypotension syndrome, which is commonly seen in the third trimester of pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Supine hypotension syndrome:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Occurs due to the pressure of the gravid uterus on the inferior vena cava (IVC) when the patient is in the supine position.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">This pressure can cause hypotension, tachycardia, and syncope.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">It is particularly dangerous during cesarean sections where spinal anesthesia can exacerbate hypotension.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A right tilt (placing a wedge under the right hip) helps to alleviate the pressure on the IVC, thereby preventing hypotension.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Semi fowlers:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The individual lies on the bed with the head elevated 30-45 degrees. This position is not suitable for a cesarean section.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Trendelenburg with legs stirrup:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This position involves having the head low and is not appropriate for a cesarean section. The reverse Trendelenburg position (head high) is also not suitable for this purpose.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Prone position:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> The prone position (lying face down) is inappropriate for cesarean sections.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During a cesarean section, the patient should be positioned supine with a wedge under the right hip to prevent supine hypotension syndrome, which is caused by the pressure of the gravid uterus on the inferior vena cava.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg 1405</span></strong></span></span></p>",
      "correct_choice_id": 23262,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6094,
      "choices": [
        {
          "id": 24345,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">LH</span></span></span></p>"
        },
        {
          "id": 24346,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">hCG</span></span></span></p>"
        },
        {
          "id": 24347,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">FSH</span></span></span></p>"
        },
        {
          "id": 24348,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">GnRH</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which hormone is secreted by placenta? (INICET NOV 2022)</span></span></p>",
      "unique_key": "Q9089478",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585436,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) hCG</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Human chorionic gonadotropin (hCG)</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the hormone secreted by the placenta. It is a glycoprotein produced by the syncytiotrophoblast cells of the placenta.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">hCG can be detected in the maternal serum or urine as early as 8-9 days post-fertilization using radioimmunoassay. In early pregnancy, hCG concentrations in plasma double every 1.4-2 days.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The primary role of hCG is to maintain the corpus luteum during the beginning of pregnancy, ensuring the continued production of progesterone, which is critical for maintaining the uterine lining and supporting pregnancy.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. LH</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Luteinizing Hormone is produced by the anterior pituitary gland, not by the placenta. It plays a key role in regulating the menstrual cycle and ovulation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. FSH</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Follicle-Stimulating Hormone is also produced by the anterior pituitary gland. It is involved in the development of ovarian follicles and the regulation of the menstrual cycle.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. GnRH</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Gonadotropin-Releasing Hormone is produced by the hypothalamus, it stimulates the anterior pituitary gland to release FSH and LH.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Human chorionic gonadotropin (hCG) is a hormone secreted by the placenta, crucial for maintaining early pregnancy by supporting the corpus luteum and progesterone production.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg266, Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 66</span></strong></span></span></p>",
      "correct_choice_id": 24346,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 54782,
      "choices": [
        {
          "id": 218593,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anomaly scan</span></span></p>"
        },
        {
          "id": 218594,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Amniocentesis</span></span></p>"
        },
        {
          "id": 218595,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chorionic villous sampling</span></span></p>"
        },
        {
          "id": 218596,
          "text": "<p><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">NIPT</span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">A patient presents at 18 weeks with low risk of trisomy on quadruple marker and high risk of NTD. What is the next best step? (INICET MAY 2024)</span></span></span></p>",
      "unique_key": "Q4941181",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585455,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Anomaly scan</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">The correct answer is <strong>Anomaly scan</strong>. This patient has a low risk of trisomy (such as Down syndrome) but a high risk of neural tube defects (NTD) based on the quadruple marker test. The quadruple marker test includes measurements of beta-hCG, unconjugated estriol, inhibin A, and alpha-fetoprotein (AFP). A high level of AFP is associated with an increased risk of NTDs, such as spina bifida.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Given the elevated risk for NTDs, the most appropriate next step is an <strong>anomaly scan</strong>, specifically a targeted imaging for fetal anomaly (TIFA) scan. This ultrasound, typically performed between 18 and 20 weeks of gestation, has a high sensitivity (up to 99%) for detecting structural anomalies, particularly neural tube defects. The scan is a non-invasive way to assess the fetus for physical defects.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option B. Amniocentesis:</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> While amniocentesis can detect chromosomal abnormalities and some structural defects, it is invasive and carries a small risk of complications. Since the concern here is structural (NTD) rather than chromosomal, and the anomaly scan is highly effective and non-invasive, amniocentesis is not the first choice.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option C. Chorionic villous sampling (CVS):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> CVS is another invasive procedure used for early genetic testing, usually performed in the first trimester. It is not useful at 18 weeks and is not the best test for detecting structural anomalies like NTDs.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Option D. NIPT (Non-Invasive Prenatal Testing):</span></strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"> NIPT is a screening tool for chromosomal aneuploidies (like trisomy 21, 18, and 13). Since the patient already has a low risk of trisomy, NIPT is unnecessary and does not address the high risk of NTD.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">In a patient with a high risk of neural tube defects identified by elevated alpha-fetoprotein on a quadruple marker test, the best next step is an anomaly scan (TIFA), which is highly effective in identifying structural fetal abnormalities, including NTDs</span></span></span></p>",
      "correct_choice_id": 218593,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20498,
      "choices": [
        {
          "id": 81954,
          "text": "<p><span style=\"font-size:12pt;\">Complete androgen insensitivity syndrome</span></p>"
        },
        {
          "id": 81955,
          "text": "<p><span style=\"font-size:12pt;\">Hypergonadotropic hypogonadism</span></p>"
        },
        {
          "id": 81956,
          "text": "<p><span style=\"font-size:12pt;\">Turner syndrome</span></p>"
        },
        {
          "id": 81957,
          "text": "<p><span style=\"font-size:12pt;\">Polycystic ovary syndrome</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">A 16-year-old girl is seen for primary amenorrhea. She has not development of breasts or hair in the pubic or axillary region. Her height is 155cm and her weight is 48 kg. She has bilateral inguinal masses. On USG examination, the uterus, fallopian tube, and ovary are absent. What is the most likely diagnosis? (NEET PG 2023)</span></p>",
      "unique_key": "Q6160855",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585406,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) Hypergonadotropic hypogonadism</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">The diagnosis based on the given clinical scenario is hypergonadotropic hypogonadism.</span></li><li><span style=\"font-size:12pt;\">In this question, bilateral inguinal masses (undescended testis), absent ovary, also there is absent uterus and fallopian tubes, all pointing to a conclusion that patient can be of XY karyotype. Because if female reproductive tract is absent, there must be mullerian inhibiting substance present which comes from Y chromosome.</span></li><li><span style=\"font-size:12pt;\">Hypergonadotropic hypogonadism can occur in disorders such as FSH or LH receptor mutations.</span></li><li><span style=\"font-size:12pt;\">Now, in a XY individual with a defect in LH/hCG receptor, testis’ Sertoli cells will produce Anti-mullerian hormone which will not let uterus, fallopian tube, cervix, upper vagina to develop. Leydi cells will not produce testosterone due to which wolffian duct development is impaired and the testes fail to descend. They appear female at birth and at puberty present with primary amenorrhea. They lack breast development and pubic hair development.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Complete androgen insensitivity syndrome</strong>: Androgen insensitivity syndrome individuals have normal breast development.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Turner syndrome</strong>: Turner's syndrome karyotype is XO.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. Polycystic ovary syndrome</strong>: In Polycystic ovarian syndrome (PCOS) ovary and uterus is present, so can’t be answer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Hypergonadotropic hypogonadism can present as primary amenorrhea with absent uterus, fallopian tubes, and ovaries in an XY individual, with bilateral inguinal masses indicating undescended testes.</span></p>",
      "correct_choice_id": 81955,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5922,
      "choices": [
        {
          "id": 23658,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational diabetes</span></span></span></p>"
        },
        {
          "id": 23659,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Rubella</span></span></span></p>"
        },
        {
          "id": 23660,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Hypothyroidism</span></span></span></p>"
        },
        {
          "id": 23661,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">﻿﻿﻿Gestational hypertension</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A baby was born at 34 weeks of pregnancy; the appearance of the baby is given below. What is the mother suffering from?</span></span><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"><span style=\"color:black\">&nbsp;</span></span></span>(NEET PG 2019)</p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\"><span style=\"color:black\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/04/02/picture7.jpg\" style=\"height:212px; width:300px\" /></span></span></span></span></p>",
      "unique_key": "Q9932158",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585412,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) Gestational diabetes </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The image shows a large for gestational age (LGA) fetus. Macrosomia is a condition where a newborn baby is significantly larger than average. This can often be identified by a higher birth weight and size compared to typical babies born at the same gestational age.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Causes of Macrosomia:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ol>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational Diabetes Mellitus (GDM) and Overt Diabetes Mellitus:</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maternal hyperglycemia leads to fetal hyperglycemia, which stimulates insulin production in the fetus. Insulin acts as a growth hormone, leading to increased fetal growth and fat deposition.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Maternal Obesity:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Increased maternal body mass index (BMI) is associated with a higher risk of delivering a macrosomic baby.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Previous Baby with Macrosomia:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A history of delivering a large baby increases the risk of subsequent babies also being large.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Post-term Pregnancy:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pregnancy extending beyond the due date increases the chance of the baby growing larger.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Excessive Weight Gain in Pregnancy:</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Significant maternal weight gain during pregnancy contributes to larger fetal size.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Conditions Not Associated with Macrosomia:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anemia and Antepartum Hemorrhage (APH):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> These conditions are typically associated with fetal growth restriction rather than macrosomia.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thrombocytopenia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This condition has no direct association with fetal weight.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Rubella:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Rubella infection during pregnancy can cause congenital rubella syndrome, which is typically associated with intrauterine growth restriction (IUGR), not macrosomia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Hypothyroidism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Maternal hypothyroidism can lead to complications such as preterm birth and low birth weight but is not directly linked to macrosomia.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Gestational Hypertension:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Gestational hypertension is associated with IUGR and preterm birth rather than increased fetal size.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Gestational diabetes is a significant risk factor for macrosomia, leading to the birth of large for gestational age (LGA) babies.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 2169, Williams Obstetrics 26<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 23658,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "ImageBased",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6102,
      "choices": [
        {
          "id": 24377,
          "text": "<p><span style=\"font-size:12pt;\">Obstetric outlet</span></p>"
        },
        {
          "id": 24378,
          "text": "<p><span style=\"font-size:12pt;\">﻿﻿﻿Anatomical outlet</span></p>"
        },
        {
          "id": 24379,
          "text": "<p><span style=\"font-size:12pt;\">﻿﻿﻿Pelvic inlet</span></p>"
        },
        {
          "id": 24380,
          "text": "<p><span style=\"font-size:12pt;\">﻿﻿﻿Mid-pelvis</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Identify the blue-colored area shown in the image below?</span>(NEET PG 2022)</p><p>&nbsp;</p><p><span style=\"color:black;font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/09/15/untitled-85.jpg\" alt=\"\" width=\"250\" height=\"320\"></span></p>",
      "unique_key": "Q7387949",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585446,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. D) Mid-pelvis</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The true pelvis is divided into 3 planes</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\">Plane of Inlet</span></li><li><span style=\"font-size:12pt;\">Plane of Mid cavity (Mid-Pelvis)</span></li><li><span style=\"font-size:12pt;\">Plane of Outlet</span></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Plane of Mid Cavity (Or Mid-Pelvis) is what is shown in the image</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Pelvic Cavity</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">This has 2 planes</span></p><p>&nbsp;</p><ol><li><span style=\"font-size:12pt;\">Plane of Greatest Dimension:&nbsp;</span><ul><li><span style=\"font-size:12pt;\">At the level of S2/3</span></li><li><span style=\"font-size:12pt;\">Circular plane; AP diameter = Transverse diameter = 12.5 cm</span></li><li><span style=\"font-size:12pt;\">Widest part of pelvis</span></li></ul></li><li><span style=\"font-size:12pt;\">Plane of Least dimension</span><ul><li><span style=\"font-size:12pt;\">At the level of S3/4</span></li><li><span style=\"font-size:12pt;\">At the level of ischial spine</span></li><li><span style=\"font-size:12pt;\">Very important plane CLINICALLY</span><ol style=\"list-style-type:lower-roman;\"><li><span style=\"font-size:12pt;\">Narrowest part of pelvis</span></li><li><span style=\"font-size:12pt;\">Internal rotation takes place here</span></li><li><span style=\"font-size:12pt;\">Origin of levator ani</span></li><li><span style=\"font-size:12pt;\">Landmark for pudendal block</span></li><li><span style=\"font-size:12pt;\">When engagement occurs, the head is felt at 0 station, i.e., at this plane</span></li><li><span style=\"font-size:12pt;\">Deep Transverse Arrest occurs here</span></li></ol></li></ul></li></ol><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. Obstetric outlet:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Refers to the lower part of the pelvic outlet, which is wider than the anatomical outlet.</span></li><li><span style=\"font-size:12pt;\">Not shown in the image.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option B. Anatomical outlet:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Refers to the narrowest part of the pelvic outlet.</span></li><li><span style=\"font-size:12pt;\">Not shown in the image.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. Pelvic inlet:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12pt;\">Marks the entrance to the true pelvis.</span></li><li><span style=\"font-size:12pt;\">Not shown in the image.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The plane of the mid-pelvis (or mid cavity) is a crucial area within the true pelvis, significant for various clinical considerations during labor and delivery.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 92 Textbook of obstetrics by JB Sharma</strong></span></p>",
      "correct_choice_id": 24380,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56950,
      "choices": [
        {
          "id": 227189,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Cervical cancer</span></span></span></p>"
        },
        {
          "id": 227190,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Pelvic organ prolapse</span></span></span></p>"
        },
        {
          "id": 227191,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Vulvar cancer</span></span></span></p>"
        },
        {
          "id": 227192,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;Uterine anomalies</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classification shown is for? (NEET PG 2024)</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/09/12/screenshot-2024-09-12-121711.jpg\" style=\"height:419px; width:700px\" /></span></span></span></p>",
      "unique_key": "Q9084870",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585451,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans.&nbsp; B) Pelvic organ prolapse</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The classification shown in the image is the <strong>Pelvic Organ Prolapse Quantification (POP-Q) system,</strong> which is used to classify pelvic organ prolapse. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Pelvic organ prolapse refers to the descent of pelvic organs, including the uterus, bladder, and rectum, into or outside of the vaginal canal. The POP-Q system is a standardized method that provides detailed measurements of the degree and location of prolapse using specific points and measurements. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">The reference point in this classification is the hymen</span></strong><span style=\"font-size:12.0pt\">, and the system documents anterior wall descent, posterior wall descent, and other prolapse details through a 3x3 grid with <strong>six specific points (Aa, Ba, C, Ap, Bp, and D) and three measurements (genital hiatus, perineal body, and total vaginal length)</strong>. This detailed system allows for accurate assessment and comparison of prolapse severity.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option A.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Cervical cancer:</strong>&nbsp; is incorrect because cervical cancer staging does not use the POP-Q system. Instead, cervical cancer staging is typically done using FIGO (International Federation of Gynecology and Obstetrics) criteria, which focus on tumor size and spread rather than anatomical descent.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C.&nbsp;</span></strong><span style=\"font-size:12.0pt\"><strong>Vulvar cancer: </strong>is incorrect. Vulvar cancer staging is also not related to pelvic organ prolapse or the POP-Q classification. It typically involves examining tumor size and invasion depth.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12pt\"><strong>Option D.</strong>&nbsp;</span><span style=\"font-size:12.0pt\"><strong>Uterine anomalies: </strong>is incorrect because uterine anomalies refer to congenital abnormalities of uterine structure and do not involve prolapse quantification. These are usually diagnosed with imaging techniques like ultrasound or MRI, not classified with a system like POP-Q.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">The POP-Q system is a specific and standardized classification method used to quantify and describe the extent of pelvic organ prolapse using detailed anatomical measurements. The hymen is the reference point for this classification.</span></span></span></p>",
      "correct_choice_id": 227190,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "CriteriaBased",
        "ImageBased",
        "RecentNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21797,
      "choices": [
        {
          "id": 87152,
          "text": "<p><span style=\"font-size:12pt;\">Biparietal diameter</span></p>"
        },
        {
          "id": 87153,
          "text": "<p><span style=\"font-size:12pt;\">Head circumference</span></p>"
        },
        {
          "id": 87154,
          "text": "<p><span style=\"font-size:12pt;\">Crown rump length</span></p>"
        },
        {
          "id": 87155,
          "text": "<p><span style=\"font-size:12pt;\">Abdominal circumference</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What is the best parameter for estimating fetal age during the first trimester using ultrasound?&nbsp;</span>(FMGE JANUARY 2023)</p>",
      "unique_key": "Q6203436",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585415,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. C) Crown rump length</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Crown rump length is the best parameter for estimating fetal age during the first trimester using ultrasound.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><img src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2023/07/19/untitled-1041.jpg\" alt=\"\" width=\"1000\" height=\"450\"></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Options A. Biparietal diameter, B. Head circumference&nbsp;</strong>and<strong> D.</strong> <strong>Abdominal circumference</strong> are parameters useful in second trimester</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective</strong>:</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">Crown rump length is the best parameter for estimating fetal age during the first trimester using ultrasound.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Dutta’s Textbook of Obstetrics 8<sup>th</sup> Edition page 84</strong></span></p>",
      "correct_choice_id": 87154,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 21792,
      "choices": [
        {
          "id": 87132,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Below pubic symphysis</span></span></span></p>"
        },
        {
          "id": 87133,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Above pubic symphysis</span></span></span></p>"
        },
        {
          "id": 87134,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Below umbilicus</span></span></span></p>"
        },
        {
          "id": 87135,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Above umbilicus</span></span></span></p>"
        }
      ],
      "text": "<p><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">What is the true statement regarding level of uterus just after delivery?</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-size:12.0pt\">&nbsp;</span></span></span>(FMGE JANUARY 2023)</p>",
      "unique_key": "Q7279946",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585414,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Below umbilicus</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/12/screenshot-2024-08-12-112353.png\" style=\"height:421px; width:1000px\" /></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Below pubic symphysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is not accurate immediately after delivery as the uterus is still quite large and palpable above the pubic symphysis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Above pubic symphysis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While this is true in a general sense postpartum, it is not specific enough to accurately describe the position immediately after delivery.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Above umbilicus:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> This is incorrect because the uterus immediately after delivery is positioned at the lower border of the umbilicus, not above it.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Immediately after delivery, the uterus is positioned at the lower border of the umbilicus, equivalent to the size it would be at 20 weeks of gestation.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span dir=\"ltr\" lang=\"EN-GB\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: D. C. Dutta&rsquo;s Textbook of Obstetrics 8<sup>th</sup> Edition page 170</span></strong></span></span></p>",
      "correct_choice_id": 87134,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5807,
      "choices": [
        {
          "id": 23198,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">37 weeks</span></span></span></p>"
        },
        {
          "id": 23199,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">39 weeks</span></span></span></p>"
        },
        {
          "id": 23200,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">38 weeks</span></span></span></p>"
        },
        {
          "id": 23201,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">40 weeks</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A pregnant woman has gestational diabetes mellitus (GDM) and her blood glucose levels are well controlled on insulin. What will be the appropriate gestational age for her delivery?&nbsp;</span></span>(INICET MAY 2018)</p>",
      "unique_key": "Q6311856",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585419,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) 39 weeks</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The appropriate timing of delivery in a pregnant woman with gestational diabetes mellitus (GDM) whose blood glucose levels are well controlled on insulin is at or after 39 weeks of gestation. This recommendation is based on the following considerations:</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Lung Maturity:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> GDM pregnancies are associated with a delay in fetal lung maturity. Routine delivery before 39 weeks is generally not recommended to avoid respiratory complications in the newborn.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Induction of Labor:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> If the patient with well-controlled GDM has not delivered spontaneously by 39 weeks, induction of labor should be scheduled at or after 39 weeks to minimize the risks associated with GDM and to ensure fetal maturity.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other important points in GDM:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Avoid Past Dates:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Delivery should not be delayed beyond the expected due date to prevent complications.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Anticipate Shoulder Dystocia:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> There is an increased risk of shoulder dystocia in infants of mothers with GDM.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Prophylactic Cesarean Section (LSCS):</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Considered if the estimated fetal weight is greater than 4.5 kg to avoid complications during vaginal delivery.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In a pregnant woman with well-controlled gestational diabetes mellitus (GDM) on insulin, the appropriate gestational age for delivery is at or after 39 weeks to ensure fetal lung maturity and reduce the risk of complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref:&nbsp;</span></strong><a href=\"https://nhm.gov.in/images/pdf/programmes/maternal-health/guidelines/National_Guidelines_for_Diagnosis_&amp;_Management_of_Gestational_Diabetes_Mellitus.pdf\" style=\"color:blue; text-decoration:underline\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">https://nhm.gov.in/images/pdf/programmes/maternal-health/guidelines/National_Guidelines_for_Diagnosis_&amp;_Management_of_Gestational_Diabetes_Mellitus.pdf</span></strong></a></span></span></p>",
      "correct_choice_id": 23199,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47292,
      "choices": [
        {
          "id": 188779,
          "text": "<p><span style=\"font-size:12.0pt;\">DHA and testosterone</span></p>"
        },
        {
          "id": 188780,
          "text": "<p><span style=\"font-size:12.0pt;\">Testosterone and AMH</span></p>"
        },
        {
          "id": 188781,
          "text": "<p><span style=\"font-size:12.0pt;\">Testosterone and DHA</span></p>"
        },
        {
          "id": 188782,
          "text": "<p><span style=\"font-size:12.0pt;\">Inhibin and testosterone</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">What hormones are secreted by the Leydig cells and the Sertoli cells respectively?&nbsp;</span>(FMGE JULY 2023)</p>",
      "unique_key": "Q6275055",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585424,
      "difficulty_level": "intermediate",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. B) Testosterone and AMH</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">In the testes, Leydig cells and Sertoli cells have distinct roles and secrete different hormones crucial for male reproductive development and function:</span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\"><strong>Leydig cells</strong>: These cells are responsible for the production of <strong>testosterone.</strong> Testosterone plays a pivotal role in the development of male secondary sexual characteristics and is crucial for the growth of the ipsilateral Wolffian duct, which develops into the male internal genitalia. Additionally, testosterone is converted to dihydrotestosterone (DHT), which is essential for the development of male external genitalia.</span></li><li><span style=\"font-size:12.0pt;\"><strong>Sertoli cells</strong>: These cells produce <strong>Anti-Mullerian Hormone (AMH),</strong> also known as Mullerian Inhibiting Substance (MIS). During male embryonic development, AMH is vital for inhibiting the growth of the Mullerian ducts, which would otherwise develop into female internal genitalia. The suppression of Mullerian duct development by AMH ensures the proper formation of male internal reproductive structures.</span></li></ul><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Note - Inhibin is secreted by Sertoli cells.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><ul><li><span style=\"font-size:12.0pt;\">Leydig cells secrete testosterone</span></li><li><span style=\"font-size:12.0pt;\">Sertoli cells secrete Anti-Mullerian Hormone (AMH) and Inhibin</span></li></ul>",
      "correct_choice_id": 188780,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6097,
      "choices": [
        {
          "id": 24357,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Uterine tenderness</span></span></span></p>"
        },
        {
          "id": 24358,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Frequent contractions</span></span></span></p>"
        },
        {
          "id": 24359,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Painless vaginal bleeding</span></span></span></p>"
        },
        {
          "id": 24360,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Mild to moderate vaginal bleeding</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Antepartum hemorrhage due to abruption shows all except?&nbsp;</span></span>(INICET NOV 2022)</p>",
      "unique_key": "Q6318871",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585438,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Painless vaginal bleeding</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Painless vaginal bleeding</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is not a feature of abruption of the placenta. It is a characteristic feature of placenta previa.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Patients with placental abruption present with sudden-onset abdominal pain, vaginal bleeding, uterine tenderness, and frequent contractions.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Abruptio placenta</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> is the partial or total separation of a normally implanted placenta before delivery, leading to bleeding and other complications.</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Uterine tenderness</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a common feature of placental abruption due to the separation of the placenta from the uterine wall.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Frequent contractions</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Increased frequency of uterine contractions is associated with placental abruption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Mild to moderate vaginal bleeding</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Vaginal bleeding of varying degrees, from mild to severe, is typically seen in placental abruption.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental abruption presents with sudden-onset abdominal pain, vaginal bleeding, uterine tenderness, and frequent contractions, but not with painless vaginal bleeding, which is characteristic of placenta previa.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: William&rsquo;s textbook of obstetrics 26<sup>th</sup> edition pg1944, &nbsp;Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 297</span></strong></span></span></p>",
      "correct_choice_id": 24359,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "DiagnosisBased",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 47288,
      "choices": [
        {
          "id": 188763,
          "text": "<p><span style=\"font-size:12.0pt;\">Low BMI</span></p>"
        },
        {
          "id": 188764,
          "text": "<p><span style=\"font-size:12.0pt;\">Tamoxifen use</span></p>"
        },
        {
          "id": 188765,
          "text": "<p><span style=\"font-size:12.0pt;\">Nulliparous</span></p>"
        },
        {
          "id": 188766,
          "text": "<p><span style=\"font-size:12.0pt;\">Ovarian cancer</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt;\">Which is NOT a hyper-estrogenic condition?&nbsp;</span>(FMGE JULY 2023)</p>",
      "unique_key": "Q1283197",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585421,
      "difficulty_level": "beginner",
      "subjects_id": [],
      "solution": "<p><span style=\"font-size:12.0pt;\"><strong>Ans. A) Low BMI</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Explanation:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Hyper-estrogenic conditions are characterized by elevated levels of estrogen. Such conditions can arise due to various factors, including hormonal imbalances, medications, and specific medical conditions.</span></p><p><br><span style=\"font-size:12.0pt;\"><strong>Low BMI</strong>: This is not typically associated with high estrogen levels. In fact, individuals with low BMI may have lower estrogen levels due to decreased adipose tissue, which is a source of estrogen production.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option B. Tamoxifen use</strong>: Tamoxifen is a selective estrogen receptor modulator (SERM) used primarily in the treatment of breast cancer. It can act as an estrogen agonist in certain tissues, potentially leading to increased estrogenic effects.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option C. Nulliparous</strong>: Nulliparous women (those who have never given birth) may have higher lifetime exposure to estrogen due to the absence of pregnancy and lactation periods, which would otherwise lower estrogen exposure.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Option D. Ovarian cancer</strong>: Certain types of ovarian cancer can lead to increased estrogen production, contributing to a hyper-estrogenic state.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">Low BMI is not associated with hyper-estrogenic conditions.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">High estrogen levels are more likely to be seen in conditions such as Tamoxifen use, nulliparity, and certain types of ovarian cancer.</span></p><p>&nbsp;</p><p><span style=\"font-size:12.0pt;\">High estrogen is a risk factors for fibroids, endometrial hyperplasia, endometrial carcinoma and endometriosis.</span></p>",
      "correct_choice_id": 188763,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "FMGE"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6025,
      "choices": [
        {
          "id": 24070,
          "text": "<p><span style=\"font-size:12pt;\">NST and fetal tone</span></p>"
        },
        {
          "id": 24071,
          "text": "<p><span style=\"font-size:12pt;\">NST and AFI</span></p>"
        },
        {
          "id": 24072,
          "text": "<p><span style=\"font-size:12pt;\">NST and breathing movements</span></p>"
        },
        {
          "id": 24073,
          "text": "<p><span style=\"font-size:12pt;\">NST and gross fetal movements</span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12pt;\">Modified biophysical profile includes?&nbsp;</span>(INICET MAY 2022)</p>",
      "unique_key": "Q7546537",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585403,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt;\"><strong>Ans. B) NST and AFI</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Modified Biophysical Profile (BPP) includes two key components: the Non-Stress Test (NST) and the Amniotic Fluid Index (AFI). This abbreviated version of the BPP focuses on assessing fetal well-being through these two measures. The NST evaluates fetal heart rate patterns in response to fetal movements, while the AFI assesses the amount of amniotic fluid, which can indicate the health of the placenta and overall fetal condition.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Other Options:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option A. NST and fetal tone:</strong> This combination is not the Modified BPP. While the NST is part of the Modified BPP, fetal tone is part of the complete Biophysical Profile but not included in the Modified BPP.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option C. NST and breathing movements</strong>: Breathing movements are part of the complete Biophysical Profile, but not included in the Modified BPP, which only uses NST and AFI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Option D. NST and gross fetal movements</strong>: Gross fetal movements are part of the full Biophysical Profile, but not included in the Modified BPP, which comprises only NST and AFI.</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Educational Objective:</strong></span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\">The Modified Biophysical Profile (BPP) includes the Non-Stress Test (NST) and the Amniotic Fluid Index (AFI).</span></p><p>&nbsp;</p><p><span style=\"font-size:12pt;\"><strong>Ref: Page no 980, Williams Obstetrics 26<sup>th</sup> edition</strong></span></p>",
      "correct_choice_id": 24071,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "INICET",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5824,
      "choices": [
        {
          "id": 23266,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha fetoprotein</span></span></span></p>"
        },
        {
          "id": 23267,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Beta HCG</span></span></span></p>"
        },
        {
          "id": 23268,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin</span></span></span></p>"
        },
        {
          "id": 23269,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">PAPP-A</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A woman with 31 weeks of gestation presents with lower abdominal pain. The clinician is concerned if the patient is in preterm labor. Which of the following is the most appropriate test in this scenario?&nbsp;</span></span>(INICET NOV 2018)</p>",
      "unique_key": "Q2964478",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585427,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Fetal fibronectin</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin (fFN) is a glycoprotein produced by fetal amnion cells and found in high concentrations in amniotic fluid. It is also found in cervico-vaginal secretions in early pregnancy (less than 22 weeks) and late pregnancy (greater than 37 weeks). The presence of fFN in cervico-vaginal secretions between 22 and 37 weeks is used as a predictor of preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A fFN level greater than 50 ng/mL is considered a significant predictor of preterm labor. The American College of Obstetricians and Gynecologists (ACOG) does not recommend routine use of fFN testing but it can be helpful in specific clinical scenarios where preterm labor is suspected.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Alpha fetoprotein:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Alpha fetoprotein (AFP) is used in prenatal screening for neural tube defects and as a component of the quadruple marker test for Down syndrome. Elevated AFP levels are associated with neural tube defects, while decreased levels can indicate Down syndrome.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Beta HCG:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Beta HCG is used in early pregnancy for confirming pregnancy and in first trimester screening for Down syndrome (where levels are elevated). It is not used for diagnosing preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. PAPP-A:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Pregnancy-associated plasma protein-A (PAPP-A) is used in first trimester screening for Down syndrome, where its levels are decreased. It is not used for diagnosing preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fetal fibronectin (fFN) testing is the most appropriate test for assessing the risk of preterm labor in a woman presenting with lower abdominal pain at 31 weeks of gestation. A positive fFN test (greater than 50 ng/mL) can help predict the likelihood of preterm labor.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Dutta&rsquo;s textbook of obstetrics 8<sup>th</sup> edition pg 366</span></strong></span></span></p>",
      "correct_choice_id": 23268,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "AIIMS",
        "ClinicalVignette",
        "InvestigationBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 20496,
      "choices": [
        {
          "id": 81946,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Acute tubular necrosis</span></span></span></p>"
        },
        {
          "id": 81947,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">DIC</span></span></span></p>"
        },
        {
          "id": 81948,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Pulmonary edema</span></span></span></p>"
        },
        {
          "id": 81949,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Thromboembolism</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">A patient was undergoing a hysteroscopic removal of a submucosal fibroid, in which a fluid deficit of 2000 mL is estimated in a patient. What is the immediate complication of this?</span></span><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">&nbsp;</span></span></span>(NEET PG 2023)</p>",
      "unique_key": "Q4557399",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585404,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. C) Pulmonary edema</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">The given clinical scenario depicts case of fluid overload, due to which pulmonary edema can develop.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<ul>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">During hysteroscopy, systemic absorption of uterine distension fluid occurs through open sinuses or vessels.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluid deficit can be estimated by manual calculation or by use of an automated fluid management system.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">When using hypotonic solutions (like glycine), the maximum allowed fluid deficit is 1000mL for healthy patients and 750mL for elderly patients or those with medical comorbidities.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">For normal saline, the maximum allowed fluid deficit is 2,500mL for healthy patients and 750mL for those with cardiovascular disease.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">If excessive absorption of fluid occurs with a hypotonic fluid; obtain serum electrolytes and the patient should be evaluated for volume overload.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Asymptomatic hyponatremia can be treated with fluid restriction and careful monitoring of urine output.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Treatment of symptomatic hyponatremia requires infusion of 3% sodium chloride and managed in intensive care.</span></span></span></li>\r\n\t<li><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluid overload from normal saline can be managed by fluid restriction; IV furosemide (20-40mg) is indicated if there is clinical or radiological evidence of pulmonary edema</span></span></span></li>\r\n</ul>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Acute tubular necrosis:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> While fluid overload can contribute to kidney injury, acute tubular necrosis is not the immediate complication in this scenario.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. DIC:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Disseminated intravascular coagulation is a serious condition involving abnormal blood clotting but is not directly related to fluid overload from hysteroscopy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Thromboembolism:</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\"> Thromboembolism involves blood clots traveling to various parts of the body but is not the immediate consequence of fluid overload.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Fluid overload during hysteroscopic surgery can lead to pulmonary edema as an immediate complication due to excessive absorption of uterine distension fluid.</span></span></span></p>",
      "correct_choice_id": 81948,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "InstrumentsBased",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 6024,
      "choices": [
        {
          "id": 24066,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Primary syphilis</span></span></span></p>"
        },
        {
          "id": 24067,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Congenital syphilis</span></span></span></p>"
        },
        {
          "id": 24068,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Secondary syphilis</span></span></span></p>"
        },
        {
          "id": 24069,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Latent syphilis</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz rule is related to?&nbsp;</span></span>(INICET MAY 2022)</p>",
      "unique_key": "Q7438783",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585402,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. B) Congenital syphilis</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong> </span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz&#39;s rule pertains to congenital syphilis. According to this rule, if a woman with untreated syphilis has multiple pregnancies, the likelihood of congenital syphilis affecting the fetus in later pregnancies decreases. This phenomenon is observed as a result of the immune system&#39;s adaptive response and potential changes in the transmission dynamics of the infection over successive pregnancies. Therefore, the rule suggests that with each subsequent pregnancy, the outcome for the fetus improves if the infection remains untreated.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Primary syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Primary syphilis involves the initial chancre or ulcer at the site of infection and is not related to Kassowitz&#39;s rule, which specifically addresses outcomes in congenital syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Secondary syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Secondary syphilis is characterized by systemic manifestations such as skin rashes and mucous membrane lesions and is not related to Kassowitz&#39;s rule.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Latent syphilis</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Latent syphilis refers to a stage where no symptoms are present but the infection is still systemic. Kassowitz&#39;s rule is not associated with latent syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Kassowitz rule states that the likelihood of congenital syphilis infection decreases with each successive pregnancy in a woman with untreated syphilis.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 343, DC Dutta&rsquo;s Textbook of Obstetrics 8<sup>th</sup> edition</span></strong></span></span></p>",
      "correct_choice_id": 24067,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5947,
      "choices": [
        {
          "id": 23758,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Epithelial cell tumor</span></span></span></p>"
        },
        {
          "id": 23759,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Germ cell tumor</span></span></span></p>"
        },
        {
          "id": 23760,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Sex cord stromal tumor</span></span></span></p>"
        },
        {
          "id": 23761,
          "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Granulosa cell tumor</span></span></span></p>"
        }
      ],
      "text": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Which class of ovarian tumor does clear cell carcinoma of the ovary belong to?&nbsp;</span></span></span>(INICET MAY 2021)</p>",
      "unique_key": "Q4952342",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585423,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ans. A) Epithelial cell tumor</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Explanation:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\"><strong>Clear cell carcinoma of the ovary</strong> is classified under epithelial cell tumors. Epithelial ovarian tumors originate from the cells that line the surface of the ovary. Clear cell carcinoma is a subtype of epithelial ovarian tumors.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Classification of ovarian tumors:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<ol>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Epithelial Cell Tumor</span></strong></span></span>\r\n\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Serous</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Mucinous</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Brenner</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Endometrioid</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> falls under this category.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Germ Cell Tumor</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Dysgerminoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Yolk sac tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Choriocarcinoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Teratoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Embryonal</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> is not classified here.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Sex Cord Stromal Tumor</span></strong></span></span>\r\n\t<ul style=\"list-style-type:circle\">\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Granulosa cell tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Thecoma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Fibroma</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Sertoli-Leydig cell tumor</span></strong></span></span></li>\r\n\t\t<li style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Clear cell carcinoma</span></strong><span style=\"font-size:12.0pt\"> is not included in this category.</span></span></span></li>\r\n\t</ul>\r\n\t</li>\r\n</ol>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p style=\"text-align:left\"><br />\r\n<span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Clear cell carcinoma of the ovary is classified as an epithelial cell tumor.</span></span></span></p>\r\n\r\n<p style=\"text-align:left\">&nbsp;</p>\r\n\r\n<p style=\"text-align:left\"><span style=\"font-size:10.5pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span dir=\"ltr\" lang=\"EN-US\" style=\"font-size:12.0pt\">Ref: Page no 291, DC Dutta&rsquo;s Textbook of Gynecology 6<sup>th</sup> edition </span></strong></span></span></p>",
      "correct_choice_id": 23758,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 23233,
      "choices": [
        {
          "id": 92896,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">ABO incompatibility </span></span></span></p>"
        },
        {
          "id": 92897,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span dir=\"ltr\" lang=\"PT-BR\" style=\"font-family:&quot;Calibri&quot;,sans-serif\">Parvovirus B19 </span></span></span></p>"
        },
        {
          "id": 92898,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Chromosomal defect </span></span></span></p>"
        },
        {
          "id": 92899,
          "text": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Alpha thalassemia major</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">All of the subsequent factors can lead to non-immune hydrops except for:&nbsp;</span></span>(INICET MAY 2023)</p>",
      "unique_key": "Q5087126",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585430,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. A) ABO incompatibility </span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Non-immune hydrops refers to fetal hydrops that occur due to causes other than those related to maternal-fetal blood group incompatibility. ABO incompatibility is an immune-related cause of hydrops, known as immune hydrops, where the mother&#39;s immune system attacks the fetus&#39;s red blood cells due to incompatible ABO blood types. Non-immune hydrops arises from various other causes such as cardiovascular issues, genetic disorders, congenital infections, hematologic disorders, placental problems, and miscellaneous conditions. </span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Parvovirus B19</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a viral infection that can cause non-immune hydrops by affecting the fetus&#39;s red blood cells, leading to severe anemia and hydrops.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Chromosomal defect</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Chromosomal abnormalities, such as trisomy 21, 18, or 13, can cause non-immune hydrops through associated congenital abnormalities or malformations.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option D. Alpha thalassemia major</span></strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: This is a hematologic disorder that results in severe anemia, which can lead to non-immune hydrops.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><strong><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:12pt\"><span style=\"font-family:&quot;Times New Roman&quot;,serif\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">ABO incompatibility leads to immune hydrops and is not a cause of non-immune hydrops.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><img alt=\"\" src=\"https://cerebellum-web-static.s3.amazonaws.com/media/public/images/2024/08/05/screenshot-2024-08-05-105104.png\" style=\"height:990px; width:1000px\" /></p>",
      "correct_choice_id": 92896,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "DiagnosisBased",
        "Factual",
        "INICET"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 5696,
      "choices": [
        {
          "id": 22756,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Retained cotyledon</span></span></span></span></p>"
        },
        {
          "id": 22757,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Endometritis</span></span></span></span></p>"
        },
        {
          "id": 22758,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placental polyp</span></span></span></span></p>"
        },
        {
          "id": 22759,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placenta previa</span></span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Which of the following is not a cause of secondary PPH?</span></span> <span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">(NEET PG 2018)</span></span></p>",
      "unique_key": "Q2387566",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585433,
      "difficulty_level": "intermediate",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ans. D) Placenta previa </span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Explanation:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placenta previa is not a cause of secondary postpartum hemorrhage (PPH). It is primarily associated with antepartum hemorrhage (bleeding before delivery) and is a risk factor for primary PPH (occurring within the first 24 hours after childbirth).</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Other options:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option A. Retained cotyledon</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Retained cotyledon can lead to secondary PPH due to retained placental fragments, causing continued uterine bleeding.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option B. Endometritis</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: Endometritis, an infection of the uterine lining, can cause secondary PPH by leading to inflammation and impaired uterine contraction.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Option C. Placental polyp</span></span></strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">: A placental polyp, which is retained placental tissue that forms a growth, can cause secondary PPH through persistent bleeding.</span></span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Placenta previa is a cause of antepartum hemorrhage and primary postpartum hemorrhage but not secondary postpartum hemorrhage.</span></span></span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\">&nbsp;</span></span></p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Aptos,sans-serif\"><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Ref: Page no 804, DC Dutta&rsquo;s Textbook of Obstetrics, 8<sup>th</sup> edition</span></span></strong></span></span></p>",
      "correct_choice_id": 22759,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "Factual",
        "OlderNEETPG"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    },
    {
      "id": 56957,
      "choices": [
        {
          "id": 227217,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Methimazole</span></span></span></p>"
        },
        {
          "id": 227218,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Carbimazole</span></span></span></p>"
        },
        {
          "id": 227219,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Iodine 131</span></span></span></p>"
        },
        {
          "id": 227220,
          "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propylthiouracil</span></span></span></p>"
        }
      ],
      "text": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">G2 at 8 weeks diagnosed to have hyperthyroidism. What is the drug of choice? (NEET PG 2024)</span></span></span></p>",
      "unique_key": "Q2186427",
      "question_audio": null,
      "question_video": null,
      "map_id": 32585447,
      "difficulty_level": "beginner",
      "subjects_id": [
        14
      ],
      "solution": "<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Ans. D) Propylthiouracil</span></strong></span></span></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><span style=\"font-size:12.0pt\">Propylthiouracil (PTU) is the preferred medication for treating hyperthyroidism in the first trimester of pregnancy. It is considered the safest option during this period because it minimizes the risk of congenital abnormalities. Methimazole and carbimazole are associated with a rare but serious condition called aplasia cutis, where infants are born with areas of missing skin. Iodine-131 is absolutely contraindicated in pregnancy due to its radioactive nature, which can lead to fetal thyroid destruction and other complications.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Other Options:</span></strong></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option A. Methimazole:</span></strong><span style=\"font-size:12.0pt\"> Although methimazole is commonly used for hyperthyroidism, it is not recommended during the first trimester of pregnancy due to its association with fetal defects like aplasia cutis, where patches of skin are absent in the newborn.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option B. Carbimazole:</span></strong><span style=\"font-size:12.0pt\"> Similar to methimazole, carbimazole is contraindicated in the first trimester due to the risk of fetal malformations, specifically aplasia cutis. It is often avoided in early pregnancy.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><span style=\"font-size:11pt\"><span style=\"font-family:Calibri,sans-serif\"><strong><span style=\"font-size:12.0pt\">Option C. Iodine 131:</span></strong><span style=\"font-size:12.0pt\"> This radioactive iodine treatment is absolutely contraindicated in pregnancy as it can cause severe fetal harm, including thyroid gland destruction and developmental issues, making it highly unsafe.</span></span></span></p>\r\n\r\n<p>&nbsp;</p>\r\n\r\n<p><strong><span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">Educational Objective:</span></span></strong></p>\r\n\r\n<p><br />\r\n<span style=\"font-size:12.0pt\"><span style=\"font-family:&quot;Calibri&quot;,sans-serif\">In the first trimester of pregnancy, propylthiouracil (PTU) is the drug of choice for hyperthyroidism due to its safer profile compared to other antithyroid medications.</span></span></p>",
      "correct_choice_id": 227220,
      "solution_audio": null,
      "solution_video": null,
      "audio_explanation_heading": null,
      "video_explanation_heading": null,
      "solution_media_position": "bottom",
      "tags": [
        "ClinicalVignette",
        "RecentNEETPG",
        "TreatmentBased"
      ],
      "explanation_video": null,
      "question_images": [],
      "explanation_images": []
    }
  ]
}